Vape 10-Q 14 Aug 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jun. 30, 2015	Aug. 14, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Vape Holdings, Inc.
Entity Central Index Key	1,455,819
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		11,967,595

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Current assets:
Cash	$ 134,059	$ 48,370
Accounts receivable	52,973	16,771
Inventory	490,184	227,530
Prepaid inventory	41,738	246,491
Other current assets	64,596	$ 44,100
Deferred financing costs	34,211
Total current assets	817,761	$ 583,262
Fixed assets, net of accumulated depreciation	121,282	106,377
Trademarks	123,150	119,575
Pending patents	20,420	14,890
TOTAL ASSETS	1,082,613	824,104
Current liabilities:
Accounts payable	131,068	216,388
Accrued expenses	121,918	$ 169,513
Customer deposits	1,275
Convertible notes payable, net of unamortized discount of $261,717 and $32,333, respectively	$ 1,034,949	$ 187,667
Related party convertible notes payable, net of unamortized discount of $4,168 at September 30, 2014		45,832
Total current liabilities	$ 1,289,210	619,400
Long term liabilities:
Convertible notes payable, long-term, net of unamortized discount of $19,800 at September 30, 2014	$ 46,667	178,200
Related party convertible notes payable, long-term, net of unamortized discount of $125,480 at September 30, 2014		199,115
Related party notes payable, long-term	$ 265,000	341,290
Warrant liability	308,029	2,464,232
Total liabilities	$ 1,908,906	$ 3,802,237
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $0.00001 par value - 100,000,000 authorized; 500,000 outstanding at June 30, 2015 and September 30, 2014
Common stock, $0.00001 par value - authorized 1,000,000,000 shares; 12,145,079 issued at June 30, 2015, 11,704,454 outstanding at June 30, 2015, and 10,032,436 issued and outstanding at September 30, 2014	$ 117	$ 100
Additional paid-in capital	24,690,014	$ 22,402,662
Treasury stock, 440,625 at June 30, 2015	(367,531)
Accumulated deficit	(25,148,893)	$ (25,380,895)
Total stockholders' deficit	(826,293)	(2,978,133)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,082,613	$ 824,104

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Balance Sheets [Abstract]
Unamortized discount convertible notes payable, current	$ 261,717	$ 32,333
Unamortized discount related party convertible notes payable, current		4,168
Unamortized discount convertible notes payable, non current		19,800
Unamortized discount related party convertible notes payable, non current		$ 125,480
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares outstanding	500,000	500,000
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	12,145,079	10,032,436
Common stock, shares outstanding	11,704,454	10,032,436
Treasury stock, shares	440,625

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		9 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenue		$ 282,331	$ 361,781	$ 1,084,233	$ 392,540
Cost of revenue [A]	[1]	157,140	356,166	604,668	365,787
Gross profit		125,191	$ 5,615	479,565	$ 26,753
Operating expenses:
Sales and Marketing [B]	[2]	188,925		554,263
Research and development		91,428	$ 109,540	143,481	$ 138,627
General and administrative [C]	[3]	488,980	1,058,660	1,862,030	1,266,511
Total operating expenses		769,333	1,168,200	2,559,774	1,405,138
Operating loss		(644,142)	(1,162,585)	(2,080,209)	(1,378,385)
Other income (expense):
Interest expense		(112,690)	(112,812)	(284,168)	(164,471)
Interest expense - related party		(4,020)	$ (82,390)	(156,170)	(91,451)
Change in warrant liability		$ 331,724		2,156,203	$ (29,528,844)
Gain on settlement				625,461
Loss on debt modification		$ (6,924)		(26,905)
Total other income (expense), net		208,090	$ (195,202)	2,314,421	$ (29,784,766)
Income (loss) before provision for income taxes		$ (436,052)	(1,357,787)	234,212	(31,163,151)
Provision for income taxes			800	2,210	800
Net income (loss)		$ (436,052)	$ (1,358,587)	$ 232,002	$ (31,163,951)
Net income (loss) available to common shareholders:
Earnings (loss) per common share - basic		$ (0.04)	$ (0.17)	$ 0.06	$ (4.41)
Earnings (loss) per common share - diluted		$ (0.04)	$ (0.17)	$ 0.05	$ (4.41)
Weighted average shares - basic		11,925,400	8,490,049	11,253,868	7,059,138
Weighted average shares - diluted		11,925,400	8,490,049	13,874,926	7,059,138
[1]	Stock-based compensation was $2,075 and $0, and $41,408 and $0 for the three and nine months ended June 30, 2015 and 2014, respectively.
[2]	Stock-based compensation was $15,200 and $0, and $110,167 and $0 for the three and nine months ended June 30, 2015 and 2014, respectively.
[3]	Stock-based compensation was $126,250 and $437,312, and $529,799 and $437,312 for the three and nine months ended June 30, 2015 and 2014, respectively.

Consolidated Statements of Ope5

Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Stock-based compensation			$ 969,577	$ 437,312
Cost of Revenue [Member]
Stock-based compensation	$ 2,075	$ 0	41,408	0
Sales and Marketing [Member]
Stock-based compensation	15,200	0	110,167	0
General and Administrative [Member]
Stock-based compensation	$ 126,250	$ 437,312	$ 529,799	$ 437,312

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit (Unaudited) - Jun. 30, 2015 - USD ($)	Total	Series A Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Treasury Stock
Balance at Sep. 30, 2014	$ (2,978,133)		$ 100	$ 22,402,662	$ (25,380,895)
Balance, Shares at Sep. 30, 2014		500,000	10,032,436
Conversion of related party notes payable and accrued interest	341,747		$ 6	341,741
Conversion of related party notes payable and accrued interest, Shares			625,478
Conversion of notes payables and accrued interest	460,233		$ 5	460,228
Conversion of notes payables and accrued interest, Shares			728,713
Conversion of unpaid wages	96,487		$ 2	96,485
Conversion of unpaid wages, Shares			158,175
Common stock issued for services	36,769		$ 1	36,768
Common stock issued for services, Shares			60,277
Common stock issued for bonuses	288,203		$ 6	288,196
Common stock issued for bonuses, Shares			440,000
Stock issued for settlement of accounts payable	100,000		$ 1	99,999
Stock issued for settlement of accounts payable, Shares			100,000
Discount on convertible note payable at 10%	252,079			252,079
Discount on related party convertible note payable at 6%	5,410			5,410
Extinguishment of related party accrued interest	1,625			1,625
Modification of convertible notes payable	23,443			23,443
Stock-based compensation - employee options	606,362			606,362
Stock-based compensation - non-employee options	75,012			75,012
Treasury stock	(367,531)		$ (4)	$ 4		$ (367,531)
Treasury stock, Share			(440,625)
Net income	232,002				$ 232,002
Balance at Jun. 30, 2015	(826,293)		$ 117	$ 24,690,014	(25,148,893)	(367,531)
Balance, Shares at Jun. 30, 2015		500,000	11,704,454
Balance at Mar. 31, 2015	(723,738)
Net income	(436,052)
Balance at Jun. 30, 2015	$ (826,293)		$ 117	$ 24,690,014	$ (25,148,893)	$ (367,531)
Balance, Shares at Jun. 30, 2015		500,000	11,704,454

Consolidated Statements of Sto7

Consolidated Statements of Stockholders' Deficit (Parenthetical) (Unaudited)	9 Months Ended
	Jun. 30, 2015
Statement of Stockholders' Equity [Abstract]
Discount on convertible note payable percentage	10.00%
Discount on related party convertible note payable	6.00%

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net income (loss)	$ 232,002	$ (31,163,951)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	49,990
Accretion of debt discounts	159,071	$ 199,715
Interest expense	147,632
Gain on change in warrant liability	(2,156,203)	$ 29,528,844
Gain on settlement	(625,461)
Loss on debt modification	$ 19,981
Fair value of officer services		$ 15,000
Common stock issued for services	$ 36,769	122,800
Stock-based compensation	969,577	437,312
Changes in operating assets and liabilities:
Accounts receivable	(36,202)	(24,865)
Inventory	(57,901)	(352,900)
Other assets	(20,496)	23,641
Accounts payable	209,680	183,436
Accrued expenses	134,873	$ 150,623
Customer deposits	1,275
Net cash used in operating activities	(935,413)	$ (880,345)
Cash flows from investing activities:
Capital expenditures	(64,895)
Purchase of trademarks and pending patents	(9,105)	$ (128,245)
Net proceeds from settlement	62,930
Net cash used in investing activities	(11,070)	$ (128,245)
Cash flows from financing activities:
Net proceeds from issuance of convertible note payable	$ 1,195,000	428,000
Net proceeds from issuances of related party convertible notes payable		324,419
Net proceeds from issuances of related party notes payable		$ 328,463
Repayments on convertible notes payable	$ (40,000)
Repayments on related party convertible notes payable	(50,000)
Repayments on related party notes payable	(72,828)
Net cash provided by financing activities	1,032,172	$ 1,080,882
Net change in cash	85,689	72,292
Cash, beginning of period	48,370	568
Cash, end of period	134,059	$ 72,860
Cash paid during the period for:
Interest	18,788
Taxes	2,209
Non-cash investing and financing activities:
Conversion of notes payable and accrued interest	460,233
Conversion of related party notes payable and accrued interest	$ 341,747	$ 64,951
Issuance of convertible note payable for services		100,000
Issuance of convertible note payable for former officer services		50,000
Issuance of common stock in connection with warrant settlement		$ 98,822
Beneficial conversion feature recorded with convertible notes payable	$ 252,079
Beneficial conversion feature recorded with related party convertible note payable	5,410
Original issue discount recorded with convertible notes payable	$ 257,489

Description of Business and Sum

Description of Business and Summary of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2015
Description of Business and Summary of Significant Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BUSINESS Vape Holdings, Inc. (“VAPE,” the “Company,” “we,” “us,” “our,” “our company”) is a holding company with its primary focus in the manufacturing and distribution of healthy and sustainable vaporization products. The Company designs, markets and distributes ceramic vaporization products under a unique brand. The Company has introduced a nonporous, non-corrosive, chemically inert medical-grade ceramic vaporization element as a healthy, sustainable alternative to traditional titanium and quartz vaporization materials, as well as lower-grade ceramic found in traditional electronic cigarettes and vaporizers. This material can be used for a wide range of applications, including stand-alone vaporization products and "E-cigs." Electronic cigarettes come in a variety of designs ranging from those that look vastly like traditional cigarettes, to larger vaporizer units which are capable of vaporizing liquid with varying viscosity. The process of vaporization is believed to eliminate the smoke, tar, ash, and other byproducts of traditional smoking by utilizing lower temperatures in a controlled electronic environment. HIVE HIVE Ceramics (“HIVE”) is the premier brand under the VAPE umbrella. HIVE manufactures and distributes a proprietarily blended ceramic vaporization element for torched, electronic and portable vaporizers with countless design and product crossover capabilities in existing and emerging markets. HIVE is dedicated to bringing the healthiest and cleanest vaporization experience possible to the market. The HIVE product line currently consists of over 15 distinct ceramic elements, including the 2 piece domeless, domeless direct inject, and HIVE’s signature domeless elements covering 10mm, 14mm and 18mm applications as well as regular elements, the HIVE Flower Cup, the HIVE Carb Cap, HIVE Stinger Dabber, the 14mm HIVE x Quave - Club Banger, and the HIVE x D-Nail 16mm and 20mm attachments. The Company has recently launched ‘HIVE Glass.’ HIVE Glass is VAPE’s newest line of products under the HIVE brand name. The HIVE GLASS line is precision made using state of the art manufacturing processes and techniques, and exclusively uses German Schott glass caliber and fittings through all production phases. The aim with HIVE Glass is to create an affordable, high quality glass product that is both aesthetically pleasing and a highly functional vaporization product. VAPE’s existing customer base and distribution network will be the catalyst for expansion of this new HIVE product line. Under HIVE Glass, the Company also buys and sells high-end collector pieces. VAPE has also recently launched ‘HIVE Supply.’ HIVE Supply is a packaging and sourcing division of VAPE designed to serve as a competitively priced, comprehensive “one-stop shop” for all medical and recreational marijuana packaging needs. As with all of VAPE’s products, HIVE Supply will operate in full compliance with all federal laws and the laws of each individual state in which it does business. HIVE Supply will focus on providing much-needed support to cannabis businesses in regards to sourcing consumer products, brand management and marketing services. HIVE Supply is currently operated out of three (3) locations: HIVE Supply in Southern California, HIVE Supply Washington in Spokane and HIVE Supply Oregon in Portland. Under HIVE Supply, the Company also buys and sells high-end manufacturing machines. In connection with its launch of HIVE Supply and HIVE Glass, the Company opened ‘THE HIVE’ retail store and gallery in Los Angeles, an end-user experience to showcase the complete line of HIVE Ceramics and HIVE Glass products, while introducing HIVE Supply and all the new products being tested and developed through each vertical. The Company intends to rely on a combination of trademark, copyright, trade secret and patent laws in the United States as well as confidentiality procedures and contractual provisions to protect future proprietary technology and its brands, as they are developed. The Company has created or acquired and continues in the process of creating and/or acquiring proprietary vaporizers and e-cigarettes, and various trademarks, patents and copyrights for brands which are developed or in development. The Company is actively engaged in improving and expanding lines of branded products through business alliances and acquisitions, as well as developing its branded retail business expansion. VAPE and its business units are organized and directed to operate strictly in accordance with all applicable state and federal laws. MANAGEMENT’S PLANS VAPE’s consolidated financial statements reflect net loss from operations of $2,080,209 during the nine months ended June 30, 2015. As of June 30, 2015, we had cash of $134,059 and a working capital deficit of $471,449. Management has subsequently obtained funding for operations described below. We believe our current liquidity will be sufficient to continue operating as a going concern through June 2016. If current and projected revenue growth does not meet our estimates, we may choose to raise additional capital through debt and/or equity transactions, renegotiate current convertible debt obligations, reduce certain overhead costs through the deferral of salaries and other means, and settle liabilities through negotiation. Currently, we cannot provide assurance that such financing will be available to us on favorable terms, or at all. If, after utilizing the existing sources of capital available to us, further capital needs are identified and if we are not successful in obtaining the financing, we may be forced to curtail our existing or planned future operations. OFFSET On January 22, 2015, the Company created a new wholly-owned subsidiary, Offset, LLC (“Offset”), which is in the business of branding, marketing, and merchandising services. Offset will serve as VAPE’s creative marketing, branding and merchandising vehicle working synergistically with VAPE’s existing product lines, sales and distribution channels, HIVE Supply retail development while expanding into unique branding, marketing and merchandising avenues both inside and outside of the cannabis industry. NOUVEAU On April 6, 2015, the Company created a new wholly-owned subsidiary, Nouveau, LLC (“Nouveau”), which is in the business of branding, marketing, and web design services. Nouveau will serve as VAPE’s creative marketing, branding, and web design vehicle working synergistically with VAPE’s existing product lines, sales and distribution channels, HIVE Supply retail development while expanding into unique branding, marketing and merchandising avenues both inside and outside of the cannabis industry. BETTERCHEM On July 1, 2015, the Company entered into a Share Exchange Agreement with BetterChem Consulting, Inc. (“BetterChem”), a Pennsylvania corporation, and its sole shareholder and the Company’s current Chief Science Officer Dr. Mark Scialdone (“Dr. Scialdone”), whereby the Company acquired a controlling 80% interest in BetterChem from Dr. Scialdone in exchange for up to 400,000 shares of the Company’s restricted common stock. In consideration for the issuance of the shares to Dr. Scialdone, the Company acquired 80 shares of the common stock of BetterChem which represents 80% of the issued and outstanding shares of BetterChem. Dr. Scialdone retained a 20% interest in BetterChem. The Share Exchange Agreement transaction closed concurrently with its execution on July 1, 2015 and was approved by Unanimous Written Consent of the Board of Directors (the “Board”) of the Company on the same date. At closing, the Company issued 250,000 shares of its common stock valued at $67,500 to BetterChem. The Company acquired an 80% controlling interest of the business in order to expand its science consulting segment and research and development. BetterChem had no assets and $8,500 of accounts payable, in which the Company assumed upon closing. An additional up to 150,000 shares of common stock to be issued to Dr. Scialdone will be subject to the following terms: 1. Due to the uncertain nature of the valuation of BetterChem, a privately held consulting business, the parties have agreed that Dr. Scialdone shall have a nonassignable contingent contractual right to receive additional shares contingent on the future gross revenues of BetterChem as follows: a. On the one year anniversary of the closing, Dr. Scialdone shall be entitled to an additional 75,000 shares if BetterChem has generated at least $100,000 in gross revenues beginning on the date of closing and up to the one year anniversary of the closing. The additional stock issuance will be calculated on a pro rata basis (i.e. If BetterChem only generates $50,000 in gross revenues in the first year then Dr. Scialdone will be entitled to only 37,500 shares). b. On the two year anniversary of the closing, Dr. Scialdone shall be entitled to an additional 75,000 shares if BetterChem has generated at least $100,000 in gross revenues beginning on the one year anniversary of the closing up to the two year anniversary of the closing. The additional stock issuance will be calculated on a pro rata basis (i.e. If BetterChem only generates $50,000 in gross revenues in the second year then Dr. Scialdone will be entitled to only 37,500 shares). 2 . In the event of a change in control of BetterChem or a sale of all or substantially all of the assets of BetterChem during the two year period, the additional 150,000 shares shall automatically vest and be payable in full to Dr. Scialdone and any salary compensation due Dr. Scialdone under the 2 year term of his employment agreement with the Company dated May 1, 2015, or extensions of that Employment Agreement which the parties may thereafter execute, shall be accelerated and shall be due and payable in full within 30 days of the event of change in control of BetterChem. In connection with the Share Exchange Agreement, on July 1, 2015, Dr. Scialdone and the Company entered into an Intellectual Property Rights Transfer Agreement (the “I.P. Agreement”) whereby Dr. Scialdone agreed to transfer and assign to Company the entire right, title and interest in and to any and all intellectual property in which Dr. Scialdone has a right to convey an interest, including intellectual property conceived, developed, reduced to practice, assigned or acquired by Dr. Scialdone prior to the date of the I.P. Agreement as well as intellectual property held, conceived, developed, reduced to practice, assigned or acquired by BetterChem. MANAGEMENT SERVICES AND REAL ESTATE SOLUTIONS VAPE also plans to leverage its management team’s vast experience in the cannabis concentrate industry to provide management, consulting, branding, real estate and compliant packaging solutions to lawfully operating participants in the cannabis industry. Although the Company plans to provide services to the industry, it does not grow, transport, harvest, or sell cannabis. Furthermore, it does not currently maintain an ownership interest in any extraction laboratories or concentrate facilities. As for its real estate services, the Company plans to hold properties in strategic locations deemed to be susceptible for large scale manufacturing and extraction of concentrates. VAPE plans to purchase this real estate, build the full-scale infrastructure needed for these cultivation and extraction laboratories and then lease the real estate, equipment and infrastructure to these compliant cultivators. The Company also plans to provide property management and leasing services to legally compliant cannabis facilities. The Company plans to provide guidance and expertise to assist in the development of standardized labs, processes and packaging. To that end, the Company plans to work closely with the leaders in cultivation, extraction and lab testing in the most relevant markets to form a positive working group to set the standard for how these products are made, packaged and responsibly advertised. VAPE plans to forge strategic relationships in the concentrate industry, develop intellectual property and standardize the build-out and process of concentrate manufacturing facilities. VAPE has already begun deploying management and consultants into areas of interest to evaluate opportunities in this rapidly growing industry. At this time, VAPE currently has not executed on any of these plans. VAPE is still evaluating opportunities in this area and plans to execute on these plans on a case-by-case basis based on the Company’s capital reserves available for such projects as well as the risks inherent in each project due to the current regulatory environment surrounding the cannabis industry. VAPE is organized and directed to operate strictly in accordance with all applicable state and federal laws.

Accounting Policies and Basis o

Accounting Policies and Basis of Presentation	9 Months Ended
	Jun. 30, 2015
Accounting Policies and Basis of Presentation [Abstract]
ACCOUNTING POLICIES AND BASIS OF PRESENTATION	NOTE 2. ACCOUNTING POLICIES AND BASIS OF PRESENTATION BASIS OF PRESENTATION The accompanying unaudited interim consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and disclosures normally included in the annual financial statements prepared in accordance with the accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments and disclosures necessary for a fair presentation of these consolidated financial statements have been included. Such adjustments consist of normal recurring adjustments. The current results are not an indication of the full year. CONSOLIDATION The consolidated financial statements include the assets, liabilities, and operating results of the Company and its wholly-owned subsidiaries, Offset and Nouveau after elimination of all material inter-company accounts and transactions. USE OF ESTIMATES The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include losses for warrant contingencies and the valuation of conversion features in notes. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Include other inputs that are directly or indirectly observable in the marketplace. Level 3 - Unobservable inputs which are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Derivative instruments include the warrant liability (Level 2). Derivative instruments are valued using standard calculations/models that are primarily based on observable inputs, including volatilities and interest rates. Therefore, derivative instruments are included in Level 2. Fair-value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2015 and September 30, 2014. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash, prepaid expenses, accounts payable, accrued liabilities, and notes payable. Fair values for these items were assumed to approximate carrying values because of their short-term nature or they are payable on demand. The following table presents the Company’s fair value hierarchy for assets measured at fair value on a recurring basis at June 30, 2015: Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 134,059 $ - $ - $ 134,059 Total assets measured at fair value $ 134,059 $ - $ - $ 134,059 Liabilities Derivative instruments $ - $ 308,029 $ - $ 308,029 Total liabilities measured at fair value $ - $ 308,029 $ - $ 308,029 The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at September 30, 2014: Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 48,370 $ - $ - $ 48,370 Total assets measured at fair value $ 48,370 $ - $ - $ 48,370 Liabilities Derivative instruments $ - $ 2,464,232 $ - $ 2,464,232 Total liabilities measured at fair value $ - $ 2,464,232 $ - $ 2,464,232 CONCENTRATION Credit Risk At times, the Company maintains cash balances at a financial institution in excess of the FDIC insurance limit. In addition, at we extend credit to customers in the normal course of business, after we evaluate the credit worthiness. The Company does not expect to take any unnecessary credit risks causing significant write-offs of potentially uncollectible accounts. Customers Two (2) customers accounted for 40% of our accounts receivable as of June 30, 2015. The loss of these customers would have a significant impact on the Company’s financial results. Suppliers Two (2) suppliers accounted for 68% of our purchases during the three months ended June 30, 2015. We purchased $60,000 in high-end glass from Kyle Tracey for HIVE Glass, which accounted for 36% of purchases during the three months ended June 30, 2015. Two (2) suppliers accounted for 70% of our purchases during the nine months ended June 30, 2015. Kyle Tracey brokered $60,000 of HIVE Glass purchases, which accounted for 11% of total purchases during the nine months ended June 30, 2015. As of June 30, 2015, $60,000 is owed to Kyle Tracey for brokering HIVE Glass sales. The loss of these suppliers would have a significant impact on the Company’s financial results. REVENUE RECOGNITION The Company recognizes revenues from product sales when (a) persuasive evidence that an agreement exists; (b) the products have been delivered; (c) the prices are fixed and determinable and not subject to refund or adjustment; and (d) collection of the amounts due is reasonably assured. Revenue is recorded when sales orders are shipped. INVENTORY Inventory is valued at the lower of cost or market, as determined primarily by the average cost inventory method, and are stated using the first-in, first-out (FIFO) method. Management will record a provision for loss for obsolete or slow moving inventory to reduce carrying amounts to net realizable value. We purchase product sourced from China which we are required to pay 50% upon placing the order. Amounts paid for products, which have not been received, are recorded as prepaid inventory. There are no amounts paid which are in dispute or considered impaired. FIXED ASSETS Fixed assets are recorded at cost and depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated life of tooling related to our ceramic products is three (3) years. The estimated life of our leasehold improvements is the lesser of the term of the related lease and useful life. IMPAIRMENT OF LONG-LIVED AND PURCHASED INTANGIBLE ASSETS The Company has adopted Accounting Standards Codification (“ASC”) 350 “Intangibles - Goodwill and Other.” The Statement requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undercounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 350 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell. Long-lived assets, such as fixed assets and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the asset is measured by comparison of its carrying amount to undiscounted future net cash flows the asset is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair market value. Estimates of expected future cash flows represent management's best estimate based on currently available information and reasonable and supportable assumptions. Any impairment recognized is permanent and may not be restored. During the three and nine months ended June 30, 2015 and 2014, the Company did not record any impairment of its trademarks and pending patents as its expected future cash flows are in excess of their carrying amounts. RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred. The costs of materials and equipment that will be acquired or constructed for research and development activities, and that have alternative future uses, both in research and development, marketing or sales, will be classified as fixed assets and depreciated over their estimated useful lives. To date, research and development costs include the research and development expenses related to prototypes of the Company’s products. During the three and nine months ended June 30, 2015 and 2014, research and development costs were $91,428 and $109,540, and $143,481 and $138,627, respectively. CONVERTIBLE DEBT Convertible debt is accounted for under the guidelines established by ASC 470-20 “Debt with Conversion and Other Options.” ASC 470-20 governs the calculation of an embedded beneficial conversion, which is treated as an additional discount to the instruments where derivative accounting (explained below) does not apply. The amount of the value of warrants and beneficial conversion feature may reduce the carrying value of the instrument to zero, but no further. The discounts relating to the initial recording of the derivatives or beneficial conversion features are accreted over the term of the debt. Many of the conversion features embedded in the Company's convertible notes are variable and are adjusted based on a discount to market prices which could cause an unlimited number of common stock to be issued. The management and board of directors currently have the ability to authorize additional shares of common stock primarily through their super voting rights under the Series A Preferred stock (See “NOTE 8 - STOCKHOLDERS’ DEFICIT”). When applicable, the Company calculates the fair value of warrants and conversion features issued with the convertible instruments using the Black-Scholes valuation method, using the same assumptions used for valuing employee options for purposes of ASC 718 “Compensation - Stock Compensation”, except that the contractual life of the warrant or conversion feature is used. Under these guidelines, the Company allocates the value of the proceeds received from a convertible debt transaction between the conversion feature and any other detachable instruments (such as warrants) on a relative fair value basis. The allocated fair value is recorded as a debt discount or premium and is amortized over the expected term of the convertible debt to interest expense. If the fair value exceeds the carrying value of the debt, an immediate charge to operations is recorded by management. Each reporting period, the Company will compute the estimated fair value of derivatives and record changes to operations. Currently no instruments are being recorded as such. The Company accounts for modifications of its BCF’s in accordance with ASC 470-50 “Modifications and Extinguishments.” ASC 470-50 requires the modification of a convertible debt instrument that changes the fair value of an embedded conversion feature and the subsequent recognition of interest expense or the associated debt instrument when the modification does not result in a debt extinguishment. DERIVATIVE FINANCIAL INSTRUMENTS Derivative financial instruments, as defined in ASC 815, “Accounting for Derivative Financial Instruments and Hedging Activities”, consist of financial instruments or other contracts that contain a notional amount and one or more underlying (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets. The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has issued financial instruments including senior convertible notes payable and freestanding stock purchase warrants with features that are either (i) not afforded equity classification, (ii) embody risks not clearly and closely related to host contracts, or (iii) may be net-cash settled by the counterparty. As required by ASC 815, in certain instances, these instruments are required to be carried as derivative liabilities, at fair value, in our consolidated financial statements. The Company estimates the fair values of derivative financial instruments using various techniques (and combinations thereof) that are considered to be consistent with objectively measuring fair values. In selecting the appropriate technique, consideration is given to, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. For less complex derivative instruments, such as free-standing warrants, the Company generally uses the Black-Scholes option valuation technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the trading market price of our common stock, which has a high-historical volatility. Since derivative financial instruments are initially and subsequently carried at fair values, the Company's operating results will reflect the volatility in these estimate and assumption changes. EARNINGS PER COMMON SHARE Basic earnings per common share is computed by dividing net income available to common shareholders by the weighted-average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing net income available to common shareholders by the combination of dilutive common share equivalents, comprised of shares issuable under the Company’s share-based compensation plans and the weighted-average number of common shares outstanding during the reporting period. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stock holders: For the Nine Months Ended June 30, Weighted average common shares outstanding used in calculating basic earnings per share 11,253,868 Effect of preferred stock 500,000 Effect of convertible notes payable 1,924,046 Effect of options and warrants 197,012 Weighted average common and common equivalent shares used in calculating diluted earnings per share 13,874,926 Net income as reported $ 232,002 Add - interest on convertible notes payable 427,240 Net income available to common stockholders $ 659,242 The Company excluded 110,000 options from the computation for the nine months ended June 30, 2015, as their exercise prices were in excess of the average closing market price of the Company’s common stock, causing their effects to be anti-dilutive using the treasury stock method. During the three months ended June 30, 2015, no options would have been included had the Company generated net income in the computation of dilutive shares outstanding using the treasury-stock method since the exercise prices exceeded the average market value of the Company's common stock. The following is a summary of outstanding securities that would have been included in the calculation of diluted shares outstanding since the exercise prices did not exceed the average market value of the Company’s common stock if the Company generated net income for the three and nine months ended June 30, 2014: For the Three Months Ended For the Nine Months Ended June 30, June 30, 2014 2014 Series A Preferred stock 5,000,000 5,000,000 Common stock options 642,400 780,976 Common stock warrants 30,701 18,804 Convertible notes 901,228 901,228 6,574,329 6,701,008 The Company would have excluded 125,000 options from the computation for the periods presented, as their exercise prices were in excess of the average closing market price of the Company’s common stock, causing their effects to be anti-dilutive using the treasury stock method. STOCK-BASED COMPENSATION ASC 718, “Share-Based Payment” requires that compensation cost related to share-based payment transactions be recognized in the consolidated financial statements. Share-based payment transactions within the scope of ASC 718 include stock options, restricted stock plans, performance-based awards, stock appreciation rights, and employee share purchase plans. The Company adopted ASC 718, which requires disclosure of the fair value and other characteristics of stock options and more prominent disclosure about the effects of an entity’s accounting policy decisions with respect to stock-based compensation on reported net loss. The Company has reflected the expense of such stock based compensation based on the fair value at the grant date for awards consistent with the provisions of ASC 718. In connection with the adoption of ASC 718, the fair value of our share-based compensation has been determined utilizing the Black-Scholes pricing model. The fair value of the options granted is amortized as compensation expense on a straight line basis over the requisite service period of the award, which is generally the vesting period. The fair value calculations involve significant judgments, assumptions, estimates and complexities that impact the amount of compensation expense to be recorded in current and future periods. Upon option exercise, the Company issues new shares of stock. The following weighted average variables were used in the Black Scholes model for all option issuances valued during the nine months ended June 30, 2015 and 2014: Nine Months Stock Price at Dividend Exercise Risk Free Volatility Average 2015 $ 0.73 -% $ 0.73 2.2 % 380 % 10.0 2014 $ 1.66 n/a $ 1.66 2.5 % 400 % 10.0 The Company's accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of Emerging Issues Task Force (“EITF”) 96-18, “Accounting for Equity Instruments That are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services”, codified into ASC 505-50. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor's performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. RECENT ACCOUNTING PRONOUNCEMENTS In May 2014, the FASB issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers”, which supersedes most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for these goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. This guidance is effective for the Company in the first quarter of fiscal year 2018 and early application is not permitted. Entities must adopt the new guidance using one of two retrospective application methods. The Company is currently evaluating the standard but does not expect it to have a material impact on our financial position, results of operations or cash flows. In August 2014, the FASB issued ASU 2014-15, which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued.2 An entity must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Financial Accounting Standards Board issues Accounting Standard Updates (“ASUs”) to amend the authoritative literature in Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of ASC. The Company believes those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company. RISKS AND UNCERTAINTIES Although forward-looking statements in this Quarterly Report reflect our good faith judgment, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading “Risk Factors” below, as well as those discussed elsewhere in this Quarterly Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report. Readers are urged to carefully review and consider the various disclosures made in this Quarterly Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

Fixed Assets

Fixed Assets	9 Months Ended
	Jun. 30, 2015
Fixed Assets [Abstract]
FIXED ASSETS	NOTE 3. FIXED ASSETS The following is a summary of fixed assets as of June 30, 2015 and September 30, 2014: June 30, September 30, Molds and Tooling $ 157,655 $ 122,555 Leasehold improvements 29,795 - Accumulated depreciation (66,168 ) (16,178 ) $ 121,282 $ 106,377 During the nine months ended June 30, 2015 and 2014, depreciation expense included in cost of revenue were $49,990 and $0, respectively.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Jun. 30, 2015
Accrued Expenses [Abstract]
ACCRUED EXPENSES	NOTE 4. ACCRUED EXPENSES The following is a summary of accrued expenses as of June 30, 2015 and September 30, 2014: June 30, September 30, Accrued interest $ 24,747 $ 16,300 Accrued interest - related party 20,480 18,325 Accrued wages and taxes 48,561 108,374 Other 28,130 26,514 $ 121,918 $ 169,513

Third Party Debt

Third Party Debt	9 Months Ended
	Jun. 30, 2015
Third Party Debt [Abstract]
THIRD PARTY DEBT	NOTE 5. THIRD PARTY DEBT CONVERTIBLE NOTES PAYABLE Beginning on February 11, 2014, the Company issued 6% Convertible Notes (the “6% Notes”) pursuant to subscription agreements to ten (10) accredited investors (the “Holders”) with the aggregate principal amount of $230,000. The 6% Notes are not secured by any collateral or any assets pledged to the Holders. The maturity dates are from February 28, 2015 to March 31, 2015, and the annual rate of interest is six percent (6%). Subject to certain limitations, the Holders can, at their sole discretion, convert the outstanding and unpaid principal and interest of their notes into fully paid and nonassessable shares of the Company’s common stock. The conversion price of these 6% Notes is the average of the fifteen (15) lowest daily VWAP’s occurring during the twenty (20) consecutive trading days immediately preceding the date each Holder elects convert all of their 6% Note minus a discount of 40%. In no event will the conversion price be less than $1.00 per share or greater than $3.00 per share. The Company had a preexisting relationship with each of the Holders, and no general solicitation or advertising was used in connection with the issuance of the 6% Notes. We recorded a discount totaling $92,000 related to the beneficial conversion feature embedded in the notes upon issuance and amortized $0 and $33,235 of the discount to interest expense during the three and nine months ended June 30, 2015, respectively. On March 12, 2015, the Company offered to pay accrued interest and modify the terms of the six (6) Holders’ outstanding 6% Notes, decreasing the conversion floor from $1.00 to $0.50 in order to encourage the noteholders to convert their promissory notes. The Company recorded a loss on debt modification of $23,443 as a result of the fair value in excess of the modified conversion floor. In March 2015, the Company paid all accrued interest on the 6% notes of $17,200. Five (5) of the six (6) holders converted in full a total of $80,000 of 6% Notes into 160,000 shares of common stock. The remaining note holder partially converted $20,000 of 6% Notes into 40,000 of common shares and extended the terms on the remaining $30,000 for six (6) months. As of June 30, 2015, there is $550 in accrued interest expense related to the one (1) remaining note and the Company recorded $2,705 and $3,607 in interest expense related to the 6% notes during the three and nine months ended June 30, 2015, respectively. On December 3, 2014, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an accredited investor (the “Investor”) pursuant to which the Company agreed to sell, and the Investor agreed to purchase, an unsecured convertible promissory note (the “Note”) in the principal amount of $560,000 less an original issue discount (“OID”) of $50,000 and transaction expenses of $10,000 for a total purchase price of $500,000. The Company also paid a finder’s fee in the amount of $25,000 in connection with this transaction, which was recorded as a discount to the note as it was paid from the proceeds. The closing under the Securities Purchase Agreement occurred on December 3, 2014. The Company received $475,000 net proceeds after transactions costs. We amortized $8,333 and $19,444 of the discount to interest expense during the three and nine months ended June 30, 2015. In addition, the Company recorded $45,940 in deferred financing costs and amortized $7,657 and $17,866 to interest expense during the three and nine months ended June 30, 2015, respectively. As of June 30, 2015, the Company capitalized $28,074 as current deferred financing costs. The Note bears interest at the rate of 10% per annum and is convertible into common stock of the Company at a conversion price per share of 70% of the average of the three (3) lowest Closing Sale Prices in the ten (10) Trading Days immediately preceding the applicable Conversion (subject to adjustment in the event of stock splits, stock dividends, and similar transactions, and in the event of subsequent sales of common stock at a lower purchase price (subject to certain exceptions))(the “Conversion Price”). In no event will the Conversion Price be less than $0.50 per share . Repayment of principal on the Note, together with accrued interest thereon, is due in twelve monthly installments, commencing six months from issuance. The Company may make such payments in cash (in which event the Company will pay a 25% premium) or, subject to certain conditions, in shares of common stock valued at the lower of the Conversion Price or 70% of the average of the three (3) lowest Closing Sale Prices in the ten (10) Trading Days immediately preceding the applicable payment date (the “Amortization Conversion Rate”). The Maturity Date of the Note is seventeen months from the date of issuance. We recorded a discount totaling $168,000 related to the beneficial conversion feature embedded in the note upon issuance. We amortized $28,000 and $65,333 of the discount to interest expense during the three and nine months ended June 30, 2015. On June 4, 2015, the Company issued Investor common stock as an amortization payment for principal and accrued interest of $46,667 and $28,871 in the form of 220,949 shares of common stock at a per share price of $0.34 and in connection the Company recorded $14,435 to interest expense for the excess fair value over accrued interest. Subsequently on July 4, 2015, Company issued Investor common stock as an amortization payment for principal and accrued interest of $46,667 and $4,295 in the form of 263,141 shares of common stock at a per share price of $0.19. As a result, as of June 30, 2015, $333,444 and $46,667, net of total unamortized discounts of $226,556 and $0 are classified as current and long-term on the accompanying consolidated balance sheet. As of June 30, 2015, there is $3,640 in accrued interest expense related to this note and the Company recorded $14,156 and $32,511 in interest expense related to this note during the three and nine months ended June 30, 2015. $2M Securities Purchase Agreement On February 10, 2015, the Company entered into a securities purchase agreement (the “February 2015 Securities Purchase Agreement”) wit The $2M Note bears interest at the rate of 10% per annum and is immediately convertible into common stock of the Company at a conversion price per share of 70% of the lowest daily VWAP in the ten (10) Trading Days immediately preceding the applicable Conversion (subject to adjustment in the event of stock splits, stock dividends, and similar transactions, and in the event of subsequent sales of common stock at a lower purchase price (subject to certain exceptions))(the “Conversion Price”). In no event will the Conversion Price be less than $0.50 per share. Repayment of principal on the $2M Note, together with accrued interest thereon, is due in twelve bi-monthly installments, commencing approximately six months from issuance. The Company may make such payments in cash (in which event the Company will pay a 25% premium) or, subject to certain conditions, in shares of common stock valued at the lower of the Conversion Price or 70% of the lowest daily VWAP in the ten (10) Trading Days immediately preceding the applicable payment date (the “Amortization Conversion Rate”). The Maturity Date of the $2M Note is twelve months from the date of issuance. During the three and nine months ended June 30, 2015, the Company received $400,000 and $800,000 toward the $2M Note with an original issue discount of $38,400 and $76,800 for net proceeds of $361,600 and $723,200, respectively. We amortized $17,600 and $22,400 of the discount to interest expense during the three and nine months ended June 30, 2015. In addition, we recorded a discount totaling $108,641 related to the beneficial conversion feature embedded in the note upon issuance. We amortized $25,113 and $36,349 of the discount to interest expense during the three and nine months ended June 30, 2015. As of June 30, 2015, $673,308, net of total unamortized discounts of $126,692 are classified as current on the accompanying consolidated balance sheet. As of June 30, 2015, there is $14,500 in accrued interest expense related to the $2M Note and the Company recorded $10,111 and $14,500 in interest expense related to this note during the three and nine months ended June 30, 2015. Subsequent to June 30, 2015, the investor has failed to provide any further proceeds beyond the initial $800,000 funded. See Note 11 for Subsequent Events for Waiver and Modification Agreement on February 2015 Securities Purchase Agreement. The Company has the ability to increase the authorized common stock of the Company in the event that the convertible notes require more shares than available. CONVERTIBLE NOTES PAYABLE, LONG-TERM On March 19, 2014, the Company issued an 8% Convertible Note to an accredited investor in exchange for the contribution of capital to the Company in the amount of $198,000 (the “Investor Note”). Per the terms of the Investor Note, the principal balance is $198,000, and is not secured by any collateral or any assets pledged to the holder. The maturity date is November 19, 2014 and interest accrues at 8% per annum. Subject to certain limitations, the holder can, at its sole discretion, convert the outstanding and unpaid principal and interest into fully paid and nonassessable shares of the Company’s common stock. The conversion price for the Investor Note is eighty percent (80%) of the average of the three (3) lowest daily closing bid prices (the 3 lowest prices will be calculated on a VWAP basis) occurring during the ten (10) consecutive Trading Days immediately preceding the applicable conversion date on which the holder elects to convert. In no event shall the conversion price be less than $1.00 or greater than $3.00. We recorded a discount totaling $158,400 related to the beneficial conversion feature embedded in the notes upon issuance. On June 2, 2014, the Investor Note was assigned in its entirety to a third party free of any liens or encumbrances. On October 28, 2014, the Company received a Notice of Conversion for the Investor Note. The noteholder converted principal of $198,000 and outstanding accrued and unpaid interest of $9,764 into 207,764 shares of restricted common stock of the Company at a per share conversion price of $1.00 in accordance with the terms of the convertible note payable. The conversion of this note was in full satisfaction of the note payable. The shares of common stock under the conversion were issued by the Company on November 7, 2014. Upon conversion, we expensed the unamortized discount of $19,800 to interest expense.

Related Party Debt

Related Party Debt	9 Months Ended
	Jun. 30, 2015
Related Party Debt [Abstract]
RELATED PARTY DEBT	NOTE 6. RELATED PARTY DEBT RELATED PARTY NOTES PAYABLE, LONG-TERM The Company had outstanding accounts payable balance to a related party (shareholder of the Company) in the amount of $15,000 as of September 30, 2013. This payable was converted into a note payable on December 7, 2013. The note payable bears interest of 6% per annum with a maturity date of December 1, 2016. As of June 30, 2015, there is $1,417 in accrued interest expense related to this note and the Company recorded $228 and $685 in interest expense related to this note during the three and nine months ended June 30, 2015. On December 7, 2013, the Company issued a note payable to a shareholder of the Company in the amount of $23,462 for monies previously borrowed from shareholder. The note is unsecured and bears interest of 6% per annum and matures on December 1, 2016. On January 22, 2015, the Company settled and paid the note and accrued interest of $1,504 for $20,000 and recorded a gain on extinguishment of the note of $3,462. On February 28, 2014, the Company issued a note payable to HIVE (the “HIVE Note”) for the principal amount of $250,000 in connection with the Hive asset acquisition. Per the terms of the HIVE Note, the maturity date is February 27, 2016 and the annual rate of interest is six percent (6%). No prepayment penalty exists. The HIVE Note is unsecured. As of June 30, 2015, there is $19,062 in accrued interest expense related to this note and the Company recorded $3,792 and $11,377 in interest expense related to this note during the three and nine months ended June 30, 2015, respectively. On May 12, 2014, the Company issued a note payable to its President, Joseph Andreae in the amount of $40,000 for monies previously borrowed during the three and six months ended March 31, 2014 (the “Andreae Note”). The note was unsecured and bears interest of 6% per annum and matures on May 1, 2016. On December 4, 2014, the Company repaid the principal balance of $40,000 and accrued interest of $1,348 in full satisfaction on the Andreae Note. On August 11, 2014, the Company issued a 6% note payable to its President, Joseph Andreae, for monies borrowed from Mr. Andreae to cover outstanding accounts payable in the amount of $12,828 (the “Andreae Note II”). Per the terms of the Andreae Note, the original principal balance was $12,828, and was not secured by any collateral or any assets pledged to the holder. The maturity date is November 30, 2014, and the annual rate of interest is six percent (6%). The monies were funded during the three and nine months ended June 30, 2014. On December 4, 2014, the Company repaid principal balance of $12,828 and accrued interest of $240 in full satisfaction of the Andreae Note II. RELATED PARTY CONVERTIBLE NOTES PAYABLE On February 18, 2014, the Company issued 8% Convertible Notes to two third parties to cover outstanding accounts payable in the amount of $20,000. Per the terms of the notes, the aggregate principal balance is $20,000, and was not secured by any collateral or any assets pledged to the holders. The maturity date is February 18, 2016, and the annual rate of interest is eight percent (8%). Subject to certain limitations, the holders can, at their sole discretion, convert the outstanding and unpaid principal and interest into fully paid and nonassessable shares of the Company’s common stock. The conversion price for the notes was the lowest market closing price per share within the previous twenty (20) market days of the date of conversion minus a discount of forty percent (40%). We recorded a discount totaling $8,000 related to the beneficial conversion feature embedded in the notes upon issuance. We amortized $1,000 and $1,667 of the discount to interest expense during the three and nine months ended June 30, 2014, respectively. On October 28, 2014, the Company received a Notice of Conversion on two (2) 8% Convertible Notes issued to third parties on February 18, 2014 to cover expenses of the Company. The noteholders converted aggregate principal of $20,000 and aggregate outstanding accrued and unpaid interest of $1,100 into an aggregate of 42,370 shares of restricted common stock of the Company at a per share conversion price of $0.498 in accordance with the terms of their convertible notes payable. The conversion of these notes was in full satisfaction of the notes payable. The shares of common stock under the conversion were issued by the Company on November 7, 2014. Upon conversion, we expensed the unamortized discount of $5,333 to interest expense. On March 17, 2014, the Company issued an 8% Convertible Note to Jerome Kaiser, former CEO, CFO and Director of the Company for services rendered to the Company in the amount of $50,000 (the “Kaiser Note”) which was charged to expense during the three months March 31, 2014. Per the terms of the Kaiser Note, the principal balance is $50,000, and is not secured by any collateral or any assets pledged to the holders. The maturity date is March 17, 2015, and the annual rate of interest is eight percent (8%). Subject to certain limitations, the holder can, at his sole discretion, convert the outstanding and unpaid principal and interest into fully paid and nonassessable shares of the Company’s common stock. The conversion price for the Kaiser Note is the market closing price of the market day immediately preceding the date of conversion minus twenty percent (20%). We recorded a discount totaling $10,000 related to the beneficial conversion feature embedded in the notes upon issuance. We amortized $1,667 and $4,167 of the discount to interest expense during the three and six months ended March 31, 2015. In March 2015, the Company paid the outstanding principal and accrued interest in satisfaction on the note of $50,000 and $4,000, respectively. RELATED PARTY CONVERTIBLE NOTES PAYABLE, LONG-TERM On February 18, 2014, the Company issued an 8% Convertible Note to Kyle Tracey for monies borrowed from Mr. Tracey to cover outstanding accounts payable in the amount of $10,612 (the “Tracey Note”). Per the terms of the Tracey Note, the original principal balance is $10,612, and was not secured by any collateral or any assets pledged to the holder. The maturity date was February 18, 2016, and the annual rate of interest is eight percent (8%). Subject to certain limitations, the holder can, at its sole discretion, convert the outstanding and unpaid principal and interest into fully paid and nonassessable shares of the Company’s common stock. The conversion price for the Tracey Note was the lowest market closing price per share within the previous twenty (20) market days of the date of conversion minus a discount of forty percent (40%). We recorded a discount totaling $4,245 related to the beneficial conversion feature embedded in the notes upon issuance. We amortized $1,415 of the discount to interest expense during the year ended September 30, 2014. On October 28, 2014, the Company received a Notice of Conversion the Tracey Note. Mr. Tracey converted principal of $10,612 and outstanding accrued and unpaid interest of $584 into 22,481 shares of restricted common stock of the Company at a per share conversion price of $0.498 in accordance with the terms of the convertible note payable. The conversion of the Tracey Note was in full satisfaction of the note payable. The shares of common stock under the conversion were issued by the Company on November 7, 2014. Upon conversion, we expensed the unamortized discount of $2,830 to interest expense. On May 12, 2014, in connection with the 6% Notes, the Company issued a note for $40,000 to Kyle Tracey, which was recorded as a related party convertible note payable. We recorded a discount totaling $16,000 related to the beneficial conversion feature embedded in the 6% note to Mr. Tracey upon issuance. We amortized $6,667 of the discount to interest expense during the year ended September 30, 2014. On October 28, 2014, the Company received a Notice of Conversion on the 6% Convertible Note issued on May 13, 2014 to Mr. Tracey (the “Tracey PPM Note”) as part of a private placement transaction in exchange for capital of $40,000. Mr. Tracey converted principal of $40,000 and outstanding accrued and unpaid interest of $1,098 into 41,098 shares of restricted common stock of the Company at a per share conversion price of $1.00 in accordance with the terms of the convertible note. The conversion of the Tracey PPM Note was in full satisfaction of the note. The shares of common stock under the conversion were issued by the Company on November 7, 2014. Upon conversion, we expensed the unamortized discount of $13,333 to interest expense. On May 12, 2014, the Company issued an 8% Convertible Note to Kyle Tracey for monies borrowed from Mr. Tracey to cover outstanding accounts payable in the amount of $11,042 (the “Tracey Note II”). Per the terms of the Tracey Note II, the original principal balance is $11,042, and was not secured by any collateral or any assets pledged to the holder. The maturity date was May 12, 2016, and the annual rate of interest is eight percent (8%). Subject to certain limitations, the holder can, at its sole discretion, convert the outstanding and unpaid principal and interest into fully paid and nonassessable shares of the Company’s common stock. The conversion price for the Tracey Note II was the lowest market closing price per share within the previous twenty (20) market days of the date of conversion minus a discount of forty percent (40%). We recorded a discount totaling $4,417 related to the beneficial conversion feature embedded in the notes upon issuance. We amortized $920 of the discount to interest expense during the year ended September 30, 2014. On October 28, 2014, the Company received a Notice of Conversion on the Tracey Note II. Tracey converted principal of $11,042 and outstanding accrued and unpaid interest of $407 into 22,989 shares of restricted common stock of the Company at a per share conversion price of $0.498 in accordance with the terms of the convertible note payable. The conver s On May 12, 2014, the Company issued an 8% Convertible Note to its Director of Business Development, Michael Cook, for monies borrowed from Mr. Cook to cover outstanding accounts payable in the amount of $11,825 (the “Cook Note”). Per the terms of the Cook Note, the original principal balance was $11,825, and was not secured by any collateral or any assets pledged to the holder. The maturity date is May 12, 2016, and the annual rate of interest is eight percent (8%). Subject to certain limitations, the holder can, at its sole discretion, convert the outstanding and unpaid principal and interest into fully paid and nonassessable shares of the Company’s common stock. The conversion price for the Cook Note was the lowest market closing price per share within the previous twenty (20) market days of the date of conversion minus a discount of forty percent (40%). We recorded a discount totaling $4,730 related to the beneficial conversion feature embedded in the notes upon issuance. We amortized $985 of the discount to interest expense during the year ended September 30, 2014. On October 28, 2014, the Company received a Notice of Conversion on the “Cook Note. Mr. Cook converted principal of $11,825 and outstanding accrued and unpaid interest of $435 into 24,619 shares of restricted common stock of the Company at a per share conversion price of $0.498 in accordance with the terms of the convertible note payable. The conversion of the Cook Note was in full satisfaction of the note payable. The shares of common stock under the conversion were issued by the Company on November 7, 2014. Upon conversion, we expensed the unamortized discount of $3,745 to interest expense. On August 11, 2014, the Company issued a second 8% Convertible Note to Mr. Cook for monies borrowed from Mr. Cook to cover outstanding accounts payable in the amount of $15,115 (the “Cook Note II”). Per the terms of the Cook Note II, the original principal balance was $15,115, and is was secured by any collateral or any assets pledged to the holder. The maturity date is August 11 2016, and the annual rate of interest is eight percent (8%). Subject to certain limitations, the holder can, at its sole discretion, convert the outstanding and unpaid principal and interest into fully paid and nonassessable shares of the Company’s common stock. The conversion price for the Cook Note II was the lowest market closing price per share within the previous twenty (20) market days of the date of conversion minus a discount of forty percent (40%). We recorded a discount totaling $6,046 related to the beneficial conversion feature embedded in the notes upon issuance. On October 28, 2014, the Company received a Notice of Conversion on the Cook Note II. Mr. Cook converted principal of $15,115 and outstanding accrued and unpaid interest of $255 into 30,864 shares of restricted common stock of the Company at a per share conversion price of $0.498 in accordance with the terms of the convertible note payable. The conversion of the Cook Note II was in full satisfaction of the note payable. The shares of common stock under the conversion were issued by the Company on November 7, 2014. Upon conversion, we expensed the unamortized discount of $5,542 to interest expense. On August 11, 2014, the Company issued an 8% Convertible Note to Mr. Tracey for monies borrowed from Mr. Tracey to cover outstanding accounts payable in the amount of $216,001 (the “Tracey Note III”). Per the terms of the Tracey Note III, the original principal balance was $216,001, and is not secured by any collateral or any assets pledged to the holder. The maturity date was August 11, 2016, and the annual rate of interest is eight percent (8%). Subject to certain limitations, the holder can, at its sole discretion, convert the outstanding and unpaid principal and interest into fully paid and nonassessable shares of the Company’s common stock. The conversion price for the Tracey Note III was the lowest market closing price per share within the previous twenty (20) market days of the date of conversion minus a discount of forty percent (40%). We recorded a discount totaling $86,401 related to the beneficial conversion feature embedded in the notes upon issuance. On October 28, 2014, the Company received a Notice of Conversion on the Tracey Note III. Mr. Tracey converted principal of $216,001 and outstanding accrued and unpaid interest of $3,645 into 441,057 shares of restricted common stock of the Company at a per share conversion price of $0.498 in accordance with the terms of the convertible note payable. The shares of common stock under the conversion were issued by the Company on November 7, 2014. Upon conversion, we expensed the unamortized discount of $79,200 to interest expense.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 30, 2015
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7. COMMITMENTS AND CONTINGENCIES Warrant Liability The Company recorded the estimated settlement liability as of March 31, 2014 for the Warrant Shares issued and the Warrants that remain outstanding and unexercised that would be entitled to the same settlement based on the number of shares expected to be issued and the market price of the Company’s common stock on the dates of the actual settlements from $4.72 per share to $7.25 per share, and market price of the first settlement of $7.25 for the unsettled claims. We believe the issuance of convertible notes in the three months ended March 31, 2014 triggered the full ratchet anti-dilution adjustment; before the provision was triggered, the fair value of the warrant liability was not significant as the exercise was so far out of the money. As a result of the above settlements with warrant holders, the Company recorded a loss on settlement of warrants of $29,528,844 during the six months ended March 31, 2014 and a long-term warrant liability of $29,430,022 as of March 31, 2014 based on 4,407,200 shares of common stock under the settlement at the Company’s closing stock prices discussed above. As of June 30, 2015, the estimated settlement liability is $308,029 based on the fair market value of 1,184,727 remaining warrants and therefore the Company recorded a gain on the change in warrant liability of $2,156,203 during the nine months ended June 30, 2015. Settlement of Company Legal Claims On December 15, 2014, the Company recorded a gain on settlement of $257,930 for a confidential settlement by and between the Company and certain shareholders and related parties as settlement for certain potential legal claims held by the Company. As a result of the settlement, the Company received net proceeds of $62,930 and vendor credits of $200,000 during the three months ended December 31, 2014. A total of $325,000 in vendor credits has been received in connection with the settlement and no further credits will be given. In January 2015, the Company received 440,625 shares from the settlement that was assigned to officers of the Company. The officers decided it was in the best interest of the Company to return these shares to the Company to be used for future strategic issuances. Accordingly, the 440,625 shares valued at $367,531 were recorded as treasury stock as of March 31, 2015, and the Company recorded a gain on settlement of $625,461 during the nine months ended June 30, 2015. Chief Science Officer On May 1, 2015, the Company appointed Dr. Mark A. Scialdone to the newly-created executive officer position of Chief Science Officer. Dr. Scialdone’s Executive Employment Agreement is for a period of two (2) years. Dr. Scialdone shall receive an annual salary of $102,000, he shall be eligible for any benefits made generally available by the Company, he shall be eligible to receive any bonuses made generally available by the Company, and he shall be reimbursed for any reasonable expenses incurred while performing his duties as the Company’s Chief Science Officer. Additionally, Dr. Scialdone is entitled to receive severance equal to six (6) months base salary if terminated without cause by the Company. The Chief Science Officer will also receive bonus compensation associated with revenue generated from consulting services revenues generated over the term of this Agreement such bonus compensation to be calculated in accordance with the schedule below. Gross Consulting Revenue* Earned: Industry Related Year 1 (from May 1, 2015 through April 30, 2016) Up to $200,000 gross revenue 2.5% From $200,000—$400,000 gross revenue 5.0% From $400,000—$600,000 gross revenue 7.5% Above $600,000 gross revenue 10.0% Year 2 (from May 1, 2016 through April 30, 2017) Up to $200,000 gross revenue 2.5% From $200,000—$400,000 gross revenue 5.0% From $400,000—$600,000 gross revenue 7.5% Above $600,000 gross revenue 10.0% Gross Revenue Earned Non Industry Related (including Legacy Business Relationships) 50/50 share (payable monthly based on actual net revenue collections. * Gross Consulting Revenue is defined herein to exclude specific reimbursable vendor costs, travel expenses including airfare. The Company agrees that in the event that revenue is realized by the Company or one of the Company's wholly owned or partially owned subsidiaries ("VAPE Affiliates"), as applicable, from the exploitation of intellectual property that is developed with Executive as the inventor or co-inventor, then the Company will pay Executive as follows: i. For licenses to parties other than the Company or VAPE Affiliates, fifteen percent (15%) of Net Royalties received by the Company and/or applicable VAPE Affiliate on all such licenses and extensions thereof in perpetuity; ii. For licenses to or other exploitation by the Company or a VAPE Affiliate, 5% of Net Profit received by the Company or applicable VAPE Affiliate from the sales of products incorporating the intellectual property in perpetuity. iii. For purposes of these payments: (1) "Net Royalties" shall be calculated by determining gross royalties received and subtracting any unrecouped out-of-pocket costs incurred by the Company and/or applicable VAPE Affiliate for filing, prosecution, licensing and patent defense directly related to the specific rights that are licensed. (2) "Net Profit" shall be calculated by determining the net profit received by the Company or applicable VAPE Affiliate from the sales of the product incorporating the invention starting with the gross revenue from sales and subtracting the costs incurred by the Company, and any returns, sales allowances and sales discounts. Officer & Director Appointments and Related Matters Pursuant to Board consent on May 11, 2015, the Company made several changes to its management structure. The Company confirmed the appointment of Dr. Mark Scialdone to the newly-created officer position of Chief Science Officer which was announced by Current Report on Form 8-K dated May 5, 2015 which is incorporated by reference herein. See above in this section for more information about Dr. Scialdone. The Company also appointed Benjamin Beaulieu, the Corporation’s current Operations Manager, to the newly-created officer position of Chief Operating Officer. Benjamin Beaulieu, 29, delivers valued experience in the implementation and integration of operational and sales systems to the VAPE Holdings executive team. Mr. Beaulieu has owned operated several multi-million-dollar retail garden supply and technology businesses. With a focus on automation and functionality, Mr. Beaulieu has successfully expanded those companies from brick and mortar locations to E-commerce superstores with global sales and partnerships with the industry’s top distributors in the United States and Canada. Mr. Beaulieu’s experience operating various companies in the ancillary MMJ markets has already improved Hive Ceramics and VAPE Holdings employee management and development. With a focus on streamlining operations Mr. Beaulieu will allow Vape Holdings, Inc. and subsidiaries to rapidly grow while combating the associated costs responsibly. The Company also decided to refocus Michael Cook, the Company's Director of Business Development, to the role of HIVE Sales and Product Development Manager in order to more effectively utilize his industry connections and streamline his involvement with product design and aggressively drive the sales department to market its various segments, such as HIVE Ceramics, HIVE Supply, and HIVE Glass. Mr. Cook’s position will report to the newly appointed Chief Operating Officer. The Company has determined that Mr. Cook’s new position will no longer result in him being considered an “Executive Officer” under the SEC’s rules and regulations. Mr. Cook was never formally appointed as an officer of the Company, but was previously determined to qualify as an executive officer under SEC rules and regulations. In addition to the officer appointments and changes above, the Board of formally appointed current CFO Allan Viernes and newly-appointed COO Benjamin Beaulieu as new members of the Board. Messrs. Viernes and Beaulieu will join CEO Kyle Tracey and President Joe Andreae on the four-person board. In connection with the appointments of Messrs. Viernes and Beaulieu to the Board, the Company increased its Board size to seven (7) members. Messrs. Viernes and Beaulieu have contributed substantially to the existing operations of the company as well as the successful launch and day-to-day oversight of new business segments. Messrs. Viernes and Beaulieu have existing employment agreements with the Company. No changes have been made to their existing compensation at this time. Enactment of Corporate Governance Measures Also on May 11, 2015, the Board reaffirmed its commitment to good corporate governance and the related disciplines of organizational excellence and enhanced transparency by commencing several new organizational initiatives. The Board believes that it is now at the proper stage in its development to support this expanded organizational structure to accelerate the Company’s future growth. Following the increase of the Board size to seven (7) members (as set forth above), the Board determined that it would take steps to fill the currently vacant positions on the Board by identifying and appointing three seasoned independent directors with a mix of finance and business, legal, applied sciences credentials and experience. The Company is searching for qualified candidates and will announce appointments as they occur. VAPE management believes the Company and its shareholders will benefit greatly from the expansion of the Company’s leadership team with the addition of new, independent directors with dynamic and diverse visions and areas of expertise. In order to properly attract the requisite Board talent, the Company previously approved a Board Compensation Plan on March 12, 2015. Concurrently with the approval of the Board Compensation Plan, 100,000 shares each were issued to Kyle Tracey and Joe Andreae as members of the Board. On May 11, 2015, the Board amended the terms of the Board Compensation Plan. Pursuant to the amended terms of the Board Compensation Plan, the Board shall issue to outside directors only, a total of 100,000 shares of restricted common stock of the Company per fiscal year of service which shares vest quarterly (i.e. 25,000 shares per quarter), As of June 30, 2015, no shares have been issued under the amended Board Compensation Plan. The Company intends to further support its existing management team with the establishment of an advisory board (the “Advisory Board”) which will consist of a wide array of outside industry experts presenting different viewpoints and areas of expertise to support the growth of existing management and the Companies expansion of new and existing business segments. In addition, the Board has authorized the creation of Audit and Compensation Committees (the “Audit Committee” and “Compensation Committee), a Company Code of Ethics, and an Insider Trading Policy to voluntarily meet advanced corporate governance guidelines. Appointments to these committees and the Advisory Board will be announced when available. Copies of the Audit Committee Charter (Ex. 99.1), Compensation Committee Charter (Ex. 99.2), Code of Ethics (Ex. 14.1) and Insider Trading Policy (Ex. 99.3) are attached as exhibits to this Quarterly Report on Form 10-Q and are incorporated by reference herein.

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended
	Jun. 30, 2015
Stockholders' Deficit [Abstract]
STOCKHOLDERS' DEFICIT	NOTE 8. STOCKHOLDERS’ DEFICIT COMMON STOCK On November 27, 2013, the Board and shareholders approved an increase in the authorized number of shares of common and preferred stock which may be issued by the Company to 1,000,000,000 shares and 100,000,000 shares, respectively. On December 3, 2013, the certificate of amendment was filed with the Secretary of State of Delaware to reflect the increase in authorized. PREFERRED STOCK On April 1, 2014, the Board formally approved the filing of a Preferred Stock Designation in connection with the commitment of 500,000 Series A Shares to HIVE on March 27, 2014 pursuant to its authority to issue blank check preferred stock as provided in the Company’s Certificate of Incorporation. Per the Certificate of Designation (the “Designation”), there are 100,000,000 shares of preferred stock authorized by the Company’s Certificate of Incorporation. The Company is authorized to issue 500,000 shares of Series A Shares pursuant to the Designation. As provided in the Designation (and as set forth in the HIVE Asset Purchase Agreement), Series A Shares are entitled to vote at a 15-1 ratio to Common Stock. Each share of preferred stock shall initially be convertible into one share of common stock (500,000 shares of common stock in the aggregate). On the two year anniversary of the transaction of HIVE, the preferred stock conversion ratio shall be adjusted as follows: a one-time pro rata adjustment of up to ten-for-one (10-1) based upon the Company generating aggregate gross revenues over the two years of at least $8,000,000 (e.g. If the Company generates only $4,000,000 in aggregate gross revenues over the two year period then the convertible ratio will adjust to 5-1). In no event will the issuance convert into more than 5,000,000 shares of common stock of the Company. On June 19, 2014, the Company formally issued the 500,000 Series A Shares to HIVE. The value ascribed to the Series A Shares was based on the historical costs of the assets acquired on March 27, 2014 from HIVE since the transfer of assets was made among entities under common control. COMMON STOCK ISSUED FOR BONUSES On March 12, 2015, the Company’s Board of Directors issued bonus stock grants of 30,000 shares of restricted common stock each to Kyle Tracey, Joseph Andreae, and Allan Viernes. In addition, a total of 60,000 shares were granted to three (3) employees. These issuances were based on the fair market value on the date of issuance immediately vested and resulted in $9,150, $9,150, and $195,200 being charged to cost of revenue, sales and marketing, and general and administrative expense during the nine months ended June 30, 2015, respectively. COMMON STOCK ISSUED FOR SERVICES On March 12, 2015, the Company’s Board of Directors issued a bonus stock grant of 60,277 shares of restricted common stock to an outside sales consultant for services performed. This issuance based on the fair market value on the date of issuance immediately vested resulting in $36,769 being charged to sales and marketing expense during the nine months ended June 30, 2015. COMMON STOCK ISSUED FOR ACCRUED WAGES On March 12, 2015, Kyle Tracey converted $59,718 of accrued wages into 97,898 shares of immediately vested restricted common stock based on the fair market value on the date of issuance. On March 12, 2015, Michael Cook converted $36,769 of accrued wages into 60,277 shares of immediately vested restricted common stock based on the fair market value on the date of issuance. COMMON STOCK ISSUED AS DIRECTOR COMPENSATION On March 12, 2015, the Company’s Board of Directors issued 100,000 shares of restricted common stock each were granted to Kyle Tracey and Joseph Andreae for serving on the Board of Directors. COMMON STOCK ISSUED FOR ACCOUNTS PAYABLE On June 1, 2015, the Board issued 100,000 shares of restricted common stock at $1.00 per share for payment of $82,648 of accrued legal services and in connection, the Company recorded prepaid legal expense of $17,352 as of June 30, 2015. This $100,000 issuance was based on the fair market value of $50,000 and additional consideration of $50,000 given on the date of issuance. WARRANTS The table below summarizes the Company’s warrant activity during the nine month period ended June 30, 2015: Shares Weighted Average Weighted Average Remaining Contractual Term Aggregate Intrinsic Warrants outstanding at September 30, 2014 1,184,726 $ 0.114 1.6 $ 7,217,234 Warrants issued - - Warrants exercised - - Cancelled/forfeited/expired - - Warrants outstanding at June 30, 2015 1,184,726 $ 0.114 0.9 $ 739,812 The Company’s warrants above are accounted for as derivative liabilities in the accompanying consolidated balance sheets. OPTIONS On June 27, 2014, the Company authorized the “2014 Incentive and Nonstatutory Stock Option Plan” (the “Plan”) whereby a maximum of 2,000,000 shares of the Company’s common stock could be granted in the form of incentive and nonstatutory stock options. If any shares of common stock subject to an award under the Plan are forfeited, expire, are settled for cash or are tendered by the participant or withheld by us to satisfy any tax withholding obligation, then, in each case, the shares subject to the award may be used again for awards under the Plan to the extent of the forfeiture, expiration, cash settlement or withholding. The stock option awards issuable under the Plan can be made up of any combination of incentive and nonstatutory stock options. The stock options will be granted at fair market value on the date of grant and will vest as directed by the Board. Incentive stock options are available to employees only whereas nonstatutory stock options are available to independent contractors and consultants of the Company. On June 27, 2014, concurrent with the formal adoption of the Plan, the Company’s Board granted a total of 1,000,000 stock options to certain employees, consultants and/or independent contractors of the Company (the “Option Grant”). The Option Grant includes options to purchase 520,000 shares granted to employees, consultants and/or independent contractors of the Company that are not executive officers. In addition, the Board determined that executive officer Michael Cook, Director of Business Development, should receive options to purchase 100,000 shares and that Kyle Tracey, Chief Executive Officer and Chairman, and Joseph Andreae, President and member of the Board, should receive options to purchase 190,000 shares each. The options were granted at the market price of the Company’s common stock at close of business ($1.66 per share) on June 27, 2014, pursuant to the Company’s standard form stock option agreements under the Plan. The options vest 25% at grant and 25% each subsequent six (6) months from the date of grant. The aggregate value of the 1,000,000 options on the grant date was $1,660,000 and the amount expensed upon the grant date was $415,000 as result of 250,000 options immediately vested. On September 30, 2014 an additional $22,312 was expensed due to the revaluing 212,500 non-employee options. The description of the incentive and nonstatutory stock options herein is qualified in its entirety by reference to the full text of the Form of Incentive Stock Option Agreement and Nonstatutory Stock Option Agreement, which are attached as Exhibits 10.2 and 10.3, respectively, to the Current Report on Form 8-K filed with the SEC on July 3, 2014. Additional Option Grants Under 2014 Stock Option Plan On October 20, 2014, the Board granted a total of 20,000 stock options to certain employees and canceled 20,000 options previously allocated (but not issued) to employees. The options were granted at the market price of the Company’s common stock at close of business ($0.83 per share). The options vest 25% at grant and 25% each subsequent six (6) months from the date of grant. The aggregate value of the 20,000 options on the grant date was $16,600 and the amount expensed upon the grant date was $4,150 as result of 5,000 options immediately vested. On December 22, 2014, the Company’s Board granted a total of 775,000 stock options to certain employees. The option grant includes options to purchase 225,000 shares granted to employees that are not executive officers. In addition, the Board determined that executive officer Michael Cook, Director of Business Development, should receive options to purchase 25,000 shares and that Kyle Tracey, Chief Executive Officer and Chairman, and Joseph Andreae, President and member of the Board, and Allan Viernes, Chief Financial Officer should receive options to purchase 175,000 shares each. The options were granted at the market price of the Company’s common stock at close of business ($0.70 per share). The options vest 25% at grant and 25% each subsequent six (6) months from the date of grant. The aggregate value of the 775,000 options on the grant date was $542,500 and the amount expensed upon the grant date was $135,625 as result of 193,750 options immediately vested. Consulting Agreements On October 20, 2014, the Company entered into consulting agreements with two consultants to provide business development and acquisition services to the Company. The consultants were each issued 100,000 options to purchase common stock of the Company by the Board as consideration for consulting services. The options were granted at the market price of the Company’s common stock at close of business ($0.83 per share). The options vest 25% at grant and 25% each subsequent six (6) months from the date of grant. The aggregate value of the 200,000 options on the grant date was $166,000 and the amount expensed upon the grant date was $41,500 as result of 50,000 options immediately vested. On December 31, 2014 an additional $3,000 was expensed due to the revaluing the 200,000 non-employee options. Surrender of Stock Options Collectively, officers, employees, and consultants of the Company decided to surrender 1,125,000 options to purchase the Company’s common stock granted from the 2014 Plan for the purpose of making options available for future strategic grants. The Chief Executive Officer, President, and Chief Operating Officer decided to forfeit 190,000 incentive statutory options each with an exercise price of $1.66. The former Business Development Officer decided to forfeit 100,000 incentive statutory options with an exercise price of $1.66. Three employees of the Company collectively decided to forfeit 117,500 incentive statutory options with an exercise price of $1.66. Consultants of the Company collectively decided to forfeit 237,500 incentive statutory options for benefit of the Company with an exercise price of $1.66. The Company cancelled these options on May 11, 2015. As of June 30, 2015, 1,005,000 options are available for issuance under the Plan. Option activity during the nine months ended June 30, 2015, was as follows: Shares Weighted Weighted Aggregate Options outstanding at September 30, 2014 1,150,000 $ 2.92 8.7 $ 4,648,294 Options granted 995,000 $ 0.73 10.0 Options exercised - $ - - Options cancelled/forfeited/expired (1,150,000 ) $ 2.92 9.2 Options outstanding at June 30, 2015 995,000 $ 0.73 9.4 $ 29,805 Options exercisable at June 30, 2015 497,500 $ 0.73 9.4 $ 14,902 The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the aggregate difference between the closing stock prices of VAPE’s common stock at the specified dates and the exercise prices for in-the-money options) that would have been received by the option holders if all in-the-money options had been exercised on the specified dates. The fair value of each option award is estimated on the date of grant using the Black-Scholes valuation model, consistent with the provisions of ASC 718. Because option-pricing models require the use of subjective assumptions, changes in these assumptions can materially affect the fair value of the options. VAPE has limited relevant historical information to support the expected exercise behavior because no exercises have taken place. During the nine months ended June 30, 2015 and 2014, $681,375 and $437,312 were recorded as stock-based compensation related to options, respectively. As of June 30, 2015, stock compensation expense and future stock compensation expense related to options for the fiscal years ending September 30, 2015 and 2016 is expected to be $681,375 and $283,300, respectively.

Intellectual Property

Intellectual Property	9 Months Ended
	Jun. 30, 2015
Intellectual Property [Abstract]
INTELLECTUAL PROPERTY	NOTE 9. INTELLECTUAL PROPERTY The Company plans to rely on a combination of trademark, copyright, trade secret and patent laws in the United States as well as confidentiality procedures and contractual provisions to protect future proprietary technology and its brands, as they are developed. The Company has begun to execute on this plan with the acquisition of the patent pending HIVE Ceramic vaporization product and the HIVE trademark as well as several pending trademark applications. The Company intends to continue to create or acquire proprietary vaporizers and e-cigarettes, and various trademarks, patents and/or copyrights for brands which are developed. TRADEMARKS On March 27, 2014, the Company and Stone Arch Studio, LLC entered into a Trademark Assignment Agreement whereby the Company acquired all right, title, priority and interest to the HIVE trademark U.S. Registration No. 44513069 as registered with the U.S. Patent and Trade Office (“USPTO”). This acquisition further protects the Company’s HIVE Ceramics brand vaporization line. In addition, the Company has filed for trademark protection with the USPTO on several additional trademarks and tradenames to be utilized by the Company in the future as the marks register. As of June 30, 2015, the Company has capitalized $123,150 in costs related to the trademarks. PATENTS On March 27, 2014, the Company formally closed its acquisition of the patent pending HIVE Ceramics vaporization technology. The Company has already begun exploiting this technology and intends to prosecute the patent application to completion. As of June 30, 2015, the Company has capitalized $20,420 in costs related to the pending patents. The Company is engaged in developing proprietary rights of the type that may be awarded patents for enhancements to its core HIVE product line as well as proprietary rights in related product lines. The Company also expects that from time to time it is in discussions to acquire additional patented technology from third parties to further grow and develop branded product lines in the vaporization market. Additionally, the Company has recently appointed Mark Scialdone, PhD as its Chief Science Officer to further expand the Company’s patent portfolio in various areas related to the Company’s industry. See Note 11 on Subsequent Events.

Segment Information

Segment Information	9 Months Ended
	Jun. 30, 2015
Segment Information [Abstract]
SEGMENT INFORMATION	NOTE 10. SEGMENT INFORMATION The Company reports information about operating segments, as well as disclosures about products and services and major customers. Operating segments are defined as revenue-producing components of the enterprise, which are generally used internally for evaluating segment performance. Management has determined that the corporate, business development, and science consulting operations of VAPE (“VAPE”), HIVE Ceramics and its product lines of HIVE Glass and HIVE Supply (shall be referred to herein collectively as “HIVE”), and Offset and Nouveau’s marketing, merchandising, and web-design operations (“MARKETING”) should be disclosed separately as management reviews consolidated financial statements for these entities separately and makes decisions independently of the other entities included within the Company’s consolidated financial statements. All intercompany transactions between the reportable segments are eliminated upon consolidation of the Company. As of June 30, 2015, the HIVE and MARKETING segments are the only revenue producing segments of the Company and are based in California. The Company evaluates the performance of its segments based on net income (loss) from operations. Certain income and charges are not allocated to segments in the Company’s management reports because they are not considered in evaluating the segments’ operating performance. The following is a summary of information about profit or loss and assets by segment: Vape Holdings, Inc. Segment Information (Unaudited) For the Three Months Ended June 30, 2015 For the Nine Months Ended June 30, 2015 VAPE HIVE MARKETING Consolidated VAPE HIVE MARKETING Consolidated Revenue Ceramics $ - $ 175,590 $ - $ 175,590 $ - $ 958,333 $ - $ 958,333 Supply - 10,382 - 10,382 - 10,382 - 10,382 Glass - 67,000 - 67,000 - 67,000 - 67,000 Merchandise - - 26,857 26,859 - - 46,018 46,018 Services - - 2,500 2,500 - - 2,500 2,500 Total revenue - 252,972 29,359 282,331 - 1,035,715 48,518 1,084,233 Cost of revenue Ceramics - 58,736 - 58,736 - 489,450 - 489,450 Supply - 10,370 - 10,370 - 10,370 - 10,370 Glass - 60,000 - 60,000 - 60,000 - 60,000 Merchandise - - 28,034 28,035 - - 44,848 44,848 Services - - - - - - - - Total cost of revenue - 129,106 28,034 157,140 - 559,820 44,848 604,668 Gross profit (loss) - 123,866 1,325 125,191 - 475,895 3,670 479,565 Operating expense: Sales and Marketing 10,125 121,206 57,594 188,925 15,903 462,779 75,581 554,263 Research and development - 91,428 - 91,428 - 143,481 - 143,481 General and administrative 223,183 234,715 31,082 488,980 898,853 872,888 90,289 1,862,030 Total operating expenses 233,308 447,349 88,676 769,333 914,756 1,479,148 165,870 2,559,774 Operating loss $ (233,308 ) $ (323,483 ) $ (87,351 ) $ (644,142 ) $ (914,756 ) $ (1,003,253 ) $ (162,200 ) $ (2,080,209 ) Other income (expense): Interest expense (112,690 ) (284,168 ) Interest expense - related party (4,020 ) (156,170 ) Change in derivative liability 331,724 2,156,203 Gain on settlement - 625,461 Loss on debt modification (6,924 ) (26,905 ) Total other income, net 208,090 2,314,421 Income before provision for income taxes (436,052 ) 234,212 Provision for income taxes - 2,210 Net income $ (436,052 ) $ 232,002

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11. SUBSEQUENT EVENTS BetterChem See Note 1 regarding the acquisition of 80% of BetterChem. Convertible Note Financing On August 5, 2015, the Company entered into a series of convertible note financings with several accredited investors totaling an aggregate of $517,000 in aggregate proceeds raised less certain fees and costs as set forth in the financing documents. The financing was disclosed on the Company’s Current Report on Form 8-K filed on August 11, 2015 and is incorporated herein by reference. On August 12, 2015, the Company entered into an additional convertible note financing transaction with an accredited investor in the principal amount of $105,000 less fees and costs. The closing under the financing occurred concurrently with the execution of the financing documents on August 12, 2015. The convertible note bears interest at the rate of 8% per annum and is convertible into common stock of the Company at any time after 180 days from issuance of the note at a conversion price per share equal to 58% of the average of the lowest trading price of the common stock in the thirteen (13) trading days immediately preceding the applicable conversion date. The Company has the option to prepay the convertible note in the first 180 days from closing subject to a prepayment penalty of 150% of principal plus interest. The maturity date of the convertible note is June 12, 2016 subject to the noteholder’s right to extend maturity an additional nine (9) month period. The foregoing descriptions of the August 12, 2015 note financing and related documentation do not purport to be complete and are qualified in their entirety by reference to the full text of the documents, which are filed as exhibits to this Quarterly Report on Form 10-Q and are incorporated herein by reference. Entry into Waiver & Modification Agreement On August 13, 2015, the Company entered into an Amendment, Waiver and Modification Agreement (the “Amendment”) to its $2M Securities Purchase Agreement and related Transaction Documents with Redwood Management, LLC including any designees and or assignees thereto. Under the terms of the Amendment, the parties agreed to reduce the $2,000,000 outstanding balance of the $2M Note to $800,000 to reflect the total amount funded under the note, to terminate the offsetting investor note securing the additional unfunded balance and to waive any past claims of default or offsetting interest on the $2M Note or investor note. See Note 5 regarding $2M Securities Purchase Agreement.

Accounting Policies and Basis20

Accounting Policies and Basis of Presentation (Policies)	9 Months Ended
	Jun. 30, 2015
Accounting Policies and Basis of Presentation [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited interim consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and disclosures normally included in the annual financial statements prepared in accordance with the accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments and disclosures necessary for a fair presentation of these consolidated financial statements have been included. Such adjustments consist of normal recurring adjustments. The current results are not an indication of the full year.
CONSOLIDATION	CONSOLIDATION The consolidated financial statements include the assets, liabilities, and operating results of the Company and its wholly-owned subsidiaries, Offset and Nouveau after elimination of all material inter-company accounts and transactions.
USE OF ESTIMATES	USE OF ESTIMATES The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include losses for warrant contingencies and the valuation of conversion features in notes.
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Include other inputs that are directly or indirectly observable in the marketplace. Level 3 - Unobservable inputs which are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Derivative instruments include the warrant liability (Level 2). Derivative instruments are valued using standard calculations/models that are primarily based on observable inputs, including volatilities and interest rates. Therefore, derivative instruments are included in Level 2. Fair-value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2015 and September 30, 2014. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash, prepaid expenses, accounts payable, accrued liabilities, and notes payable. Fair values for these items were assumed to approximate carrying values because of their short-term nature or they are payable on demand. The following table presents the Company’s fair value hierarchy for assets measured at fair value on a recurring basis at June 30, 2015: Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 134,059 $ - $ - $ 134,059 Total assets measured at fair value $ 134,059 $ - $ - $ 134,059 Liabilities Derivative instruments $ - $ 308,029 $ - $ 308,029 Total liabilities measured at fair value $ - $ 308,029 $ - $ 308,029 The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at September 30, 2014: Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 48,370 $ - $ - $ 48,370 Total assets measured at fair value $ 48,370 $ - $ - $ 48,370 Liabilities Derivative instruments $ - $ 2,464,232 $ - $ 2,464,232 Total liabilities measured at fair value $ - $ 2,464,232 $ - $ 2,464,232
CONCENTRATION	CONCENTRATION Credit Risk At times, the Company maintains cash balances at a financial institution in excess of the FDIC insurance limit. In addition, at we extend credit to customers in the normal course of business, after we evaluate the credit worthiness. The Company does not expect to take any unnecessary credit risks causing significant write-offs of potentially uncollectible accounts. Customers Two (2) customers accounted for 40% of our accounts receivable as of June 30, 2015. The loss of these customers would have a significant impact on the Company’s financial results. Suppliers Two (2) suppliers accounted for 68% of our purchases during the three months ended June 30, 2015. We purchased $60,000 in high-end glass from Kyle Tracey for HIVE Glass, which accounted for 36% of purchases during the three months ended June 30, 2015. Two (2) suppliers accounted for 70% of our purchases during the nine months ended June 30, 2015. Kyle Tracey brokered $60,000 of HIVE Glass purchases, which accounted for 11% of total purchases during the nine months ended June 30, 2015. As of June 30, 2015, $60,000 is owed to Kyle Tracey for brokering HIVE Glass sales. The loss of these suppliers would have a significant impact on the Company’s financial results.
REVENUE RECOGNITION	REVENUE RECOGNITION The Company recognizes revenues from product sales when (a) persuasive evidence that an agreement exists; (b) the products have been delivered; (c) the prices are fixed and determinable and not subject to refund or adjustment; and (d) collection of the amounts due is reasonably assured. Revenue is recorded when sales orders are shipped.
INVENTORY	INVENTORY Inventory is valued at the lower of cost or market, as determined primarily by the average cost inventory method, and are stated using the first-in, first-out (FIFO) method. Management will record a provision for loss for obsolete or slow moving inventory to reduce carrying amounts to net realizable value. We purchase product sourced from China which we are required to pay 50% upon placing the order. Amounts paid for products, which have not been received, are recorded as prepaid inventory. There are no amounts paid which are in dispute or considered impaired.
FIXED ASSETS	FIXED ASSETS Fixed assets are recorded at cost and depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated life of tooling related to our ceramic products is three (3) years. The estimated life of our leasehold improvements is the lesser of the term of the related lease and useful life.
IMPAIRMENT OF LONG-LIVED AND PURCHASED INTANGIBLE ASSETS	IMPAIRMENT OF LONG-LIVED AND PURCHASED INTANGIBLE ASSETS The Company has adopted Accounting Standards Codification (“ASC”) 350 “Intangibles - Goodwill and Other.” The Statement requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undercounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 350 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell. Long-lived assets, such as fixed assets and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the asset is measured by comparison of its carrying amount to undiscounted future net cash flows the asset is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair market value. Estimates of expected future cash flows represent management's best estimate based on currently available information and reasonable and supportable assumptions. Any impairment recognized is permanent and may not be restored. During the three and nine months ended June 30, 2015 and 2014, the Company did not record any impairment of its trademarks and pending patents as its expected future cash flows are in excess of their carrying amounts.
RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred. The costs of materials and equipment that will be acquired or constructed for research and development activities, and that have alternative future uses, both in research and development, marketing or sales, will be classified as fixed assets and depreciated over their estimated useful lives. To date, research and development costs include the research and development expenses related to prototypes of the Company’s products. During the three and nine months ended June 30, 2015 and 2014, research and development costs were $91,428 and $109,540, and $143,481 and $138,627, respectively.
CONVERTIBLE DEBT	CONVERTIBLE DEBT Convertible debt is accounted for under the guidelines established by ASC 470-20 “Debt with Conversion and Other Options.” ASC 470-20 governs the calculation of an embedded beneficial conversion, which is treated as an additional discount to the instruments where derivative accounting (explained below) does not apply. The amount of the value of warrants and beneficial conversion feature may reduce the carrying value of the instrument to zero, but no further. The discounts relating to the initial recording of the derivatives or beneficial conversion features are accreted over the term of the debt. Many of the conversion features embedded in the Company's convertible notes are variable and are adjusted based on a discount to market prices which could cause an unlimited number of common stock to be issued. The management and board of directors currently have the ability to authorize additional shares of common stock primarily through their super voting rights under the Series A Preferred stock (See “NOTE 8 - STOCKHOLDERS’ DEFICIT”). When applicable, the Company calculates the fair value of warrants and conversion features issued with the convertible instruments using the Black-Scholes valuation method, using the same assumptions used for valuing employee options for purposes of ASC 718 “Compensation - Stock Compensation”, except that the contractual life of the warrant or conversion feature is used. Under these guidelines, the Company allocates the value of the proceeds received from a convertible debt transaction between the conversion feature and any other detachable instruments (such as warrants) on a relative fair value basis. The allocated fair value is recorded as a debt discount or premium and is amortized over the expected term of the convertible debt to interest expense. If the fair value exceeds the carrying value of the debt, an immediate charge to operations is recorded by management. Each reporting period, the Company will compute the estimated fair value of derivatives and record changes to operations. Currently no instruments are being recorded as such. The Company accounts for modifications of its BCF’s in accordance with ASC 470-50 “Modifications and Extinguishments.” ASC 470-50 requires the modification of a convertible debt instrument that changes the fair value of an embedded conversion feature and the subsequent recognition of interest expense or the associated debt instrument when the modification does not result in a debt extinguishment.
DERIVATIVE FINANCIAL INSTRUMENTS	DERIVATIVE FINANCIAL INSTRUMENTS Derivative financial instruments, as defined in ASC 815, “Accounting for Derivative Financial Instruments and Hedging Activities”, consist of financial instruments or other contracts that contain a notional amount and one or more underlying (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets. The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has issued financial instruments including senior convertible notes payable and freestanding stock purchase warrants with features that are either (i) not afforded equity classification, (ii) embody risks not clearly and closely related to host contracts, or (iii) may be net-cash settled by the counterparty. As required by ASC 815, in certain instances, these instruments are required to be carried as derivative liabilities, at fair value, in our consolidated financial statements. The Company estimates the fair values of derivative financial instruments using various techniques (and combinations thereof) that are considered to be consistent with objectively measuring fair values. In selecting the appropriate technique, consideration is given to, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. For less complex derivative instruments, such as free-standing warrants, the Company generally uses the Black-Scholes option valuation technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the trading market price of our common stock, which has a high-historical volatility. Since derivative financial instruments are initially and subsequently carried at fair values, the Company's operating results will reflect the volatility in these estimate and assumption changes.
EARNINGS PER COMMON SHARE	EARNINGS PER COMMON SHARE Basic earnings per common share is computed by dividing net income available to common shareholders by the weighted-average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing net income available to common shareholders by the combination of dilutive common share equivalents, comprised of shares issuable under the Company’s share-based compensation plans and the weighted-average number of common shares outstanding during the reporting period. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stock holders: For the Nine Months Ended June 30, Weighted average common shares outstanding used in calculating basic earnings per share 11,253,868 Effect of preferred stock 500,000 Effect of convertible notes payable 1,924,046 Effect of options and warrants 197,012 Weighted average common and common equivalent shares used in calculating diluted earnings per share 13,874,926 Net income as reported $ 232,002 Add - interest on convertible notes payable 427,240 Net income available to common stockholders $ 659,242 The Company excluded 110,000 options from the computation for the nine months ended June 30, 2015, as their exercise prices were in excess of the average closing market price of the Company’s common stock, causing their effects to be anti-dilutive using the treasury stock method. During the three months ended June 30, 2015, no options would have been included had the Company generated net income in the computation of dilutive shares outstanding using the treasury-stock method since the exercise prices exceeded the average market value of the Company's common stock. The following is a summary of outstanding securities that would have been included in the calculation of diluted shares outstanding since the exercise prices did not exceed the average market value of the Company’s common stock if the Company generated net income for the three and nine months ended June 30, 2014: For the Three Months Ended For the Nine Months Ended June 30, June 30, 2014 2014 Series A Preferred stock 5,000,000 5,000,000 Common stock options 642,400 780,976 Common stock warrants 30,701 18,804 Convertible notes 901,228 901,228 6,574,329 6,701,008 The Company would have excluded 125,000 options from the computation for the periods presented, as their exercise prices were in excess of the average closing market price of the Company’s common stock, causing their effects to be anti-dilutive using the treasury stock method.
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION ASC 718, “Share-Based Payment” requires that compensation cost related to share-based payment transactions be recognized in the consolidated financial statements. Share-based payment transactions within the scope of ASC 718 include stock options, restricted stock plans, performance-based awards, stock appreciation rights, and employee share purchase plans. The Company adopted ASC 718, which requires disclosure of the fair value and other characteristics of stock options and more prominent disclosure about the effects of an entity’s accounting policy decisions with respect to stock-based compensation on reported net loss. The Company has reflected the expense of such stock based compensation based on the fair value at the grant date for awards consistent with the provisions of ASC 718. In connection with the adoption of ASC 718, the fair value of our share-based compensation has been determined utilizing the Black-Scholes pricing model. The fair value of the options granted is amortized as compensation expense on a straight line basis over the requisite service period of the award, which is generally the vesting period. The fair value calculations involve significant judgments, assumptions, estimates and complexities that impact the amount of compensation expense to be recorded in current and future periods. Upon option exercise, the Company issues new shares of stock. The following weighted average variables were used in the Black Scholes model for all option issuances valued during the nine months ended June 30, 2015 and 2014: Nine Months Stock Price at Dividend Exercise Risk Free Volatility Average 2015 $ 0.73 -% $ 0.73 2.2 % 380 % 10.0 2014 $ 1.66 n/a $ 1.66 2.5 % 400 % 10.0 The Company's accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of Emerging Issues Task Force (“EITF”) 96-18, “Accounting for Equity Instruments That are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services”, codified into ASC 505-50. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor's performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In May 2014, the FASB issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers”, which supersedes most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for these goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. This guidance is effective for the Company in the first quarter of fiscal year 2018 and early application is not permitted. Entities must adopt the new guidance using one of two retrospective application methods. The Company is currently evaluating the standard but does not expect it to have a material impact on our financial position, results of operations or cash flows. In August 2014, the FASB issued ASU 2014-15, which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued.2 An entity must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Financial Accounting Standards Board issues Accounting Standard Updates (“ASUs”) to amend the authoritative literature in Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of ASC. The Company believes those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company.
RISKS AND UNCERTAINTIES	RISKS AND UNCERTAINTIES Although forward-looking statements in this Quarterly Report reflect our good faith judgment, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading “Risk Factors” below, as well as those discussed elsewhere in this Quarterly Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report. Readers are urged to carefully review and consider the various disclosures made in this Quarterly Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

Accounting Policies and Basis21

Accounting Policies and Basis of Presentation (Tables)	9 Months Ended
	Jun. 30, 2015
Accounting Policies and Basis of Presentation [Abstract]
Schedule of assets and liabilities measured at fair value on a recurring basis	Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 134,059 $ - $ - $ 134,059 Total assets measured at fair value $ 134,059 $ - $ - $ 134,059 Liabilities Derivative instruments $ - $ 308,029 $ - $ 308,029 Total liabilities measured at fair value $ - $ 308,029 $ - $ 308,029 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 48,370 $ - $ - $ 48,370 Total assets measured at fair value $ 48,370 $ - $ - $ 48,370 Liabilities Derivative instruments $ - $ 2,464,232 $ - $ 2,464,232 Total liabilities measured at fair value $ - $ 2,464,232 $ - $ 2,464,232
Schedule of reconciliation of net income available to common stock holders	For the Nine Months Ended June 30, Weighted average common shares outstanding used in calculating basic earnings per share 11,253,868 Effect of preferred stock 500,000 Effect of convertible notes payable 1,924,046 Effect of options and warrants 197,012 Weighted average common and common equivalent shares used in calculating diluted earnings per share 13,874,927 Net income as reported $ 232,002 Add - interest on convertible notes payable 427,240 Net income available to common stockholders $ 659,242
Schedule of securities to be included in diluted share calculation	For the Three Months Ended For the Nine Months Ended June 30, June 30, 2014 2014 Series A Preferred stock 5,000,000 5,000,000 Common stock options 642,400 780,976 Common stock warrants 30,701 18,804 Convertible notes 901,228 901,228 6,574,329 6,701,008
Summary of weighted average variables used in the Black Scholes model	Nine Months Stock Price at Dividend Exercise Risk Free Volatility Average 2015 $ 0.73 -% $ 0.73 2.2 % 380 % 10.0 2014 $ 1.66 n/a $ 1.66 2.5 % 400 % 10.0

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Jun. 30, 2015
Fixed Assets [Abstract]
Summary of fixed assets	June 30, September 30, Molds and Tooling $ 157,655 $ 122,555 Leasehold improvements 29,795 - Accumulated depreciation (66,168 ) (16,178 ) $ 121,282 $ 106,377

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Jun. 30, 2015
Accrued Expenses [Abstract]
Summary of accrued expenses	June 30, September 30, Accrued interest $ 24,747 $ 16,300 Accrued interest - related party 20,480 18,325 Accrued wages and taxes 48,561 108,374 Other 28,130 26,514 $ 121,918 $ 169,513

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Jun. 30, 2015
Commitments and Contingencies [Abstract]
Schedule of bonus compensation rate calculated with revenue	Year 1 (from May 1, 2015 through April 30, 2016) Up to $200,000 gross revenue 2.5% From $200,000—$400,000 gross revenue 5.0% From $400,000—$600,000 gross revenue 7.5% Above $600,000 gross revenue 10.0% Year 2 (from May 1, 2016 through April 30, 2017) Up to $200,000 gross revenue 2.5% From $200,000—$400,000 gross revenue 5.0% From $400,000—$600,000 gross revenue 7.5% Above $600,000 gross revenue 10.0%

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	9 Months Ended
	Jun. 30, 2015
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of option activity	Shares Weighted Weighted Aggregate Options outstanding at September 30, 2014 1,150,000 $ 2.92 8.7 $ 4,648,294 Options granted 995,000 $ 0.73 10.0 Options exercised - $ - - Options cancelled/forfeited/expired (1,150,000 ) $ 2.92 9.2 Options outstanding at June 30, 2015 995,000 $ 0.73 9.4 $ 29,805 Options exercisable at June 30, 2015 497,500 $ 0.73 9.4 $ 14,902
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of option activity	Shares Weighted Average Weighted Average Remaining Contractual Term Aggregate Intrinsic Warrants outstanding at September 30, 2014 1,184,726 $ 0.114 1.6 $ 7,217,234 Warrants issued - - Warrants exercised - - Cancelled/forfeited/expired - - Warrants outstanding at June 30, 2015 1,184,726 $ 0.114 0.9 $ 739,812

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Jun. 30, 2015
Segment Information [Abstract]
Schedule of segment reporting information	For the Three Months Ended June 30, 2015 For the Nine Months Ended June 30, 2015 VAPE HIVE MARKETING Consolidated VAPE HIVE MARKETING Consolidated Revenue Ceramics $ - $ 175,590 $ - $ 175,590 $ - $ 958,333 $ - $ 958,333 Supply - 10,382 - 10,382 - 10,382 - 10,382 Glass - 67,000 - 67,000 - 67,000 - 67,000 Merchandise - - 26,857 26,859 - - 46,018 46,018 Services - - 2,500 2,500 - - 2,500 2,500 Total revenue - 252,972 29,359 282,331 - 1,035,715 48,518 1,084,233 Cost of revenue Ceramics - 58,736 - 58,736 - 489,450 - 489,450 Supply - 10,370 - 10,370 - 10,370 - 10,370 Glass - 60,000 - 60,000 - 60,000 - 60,000 Merchandise - - 28,034 28,035 - - 44,848 44,848 Services - - - - - - - - Total cost of revenue - 129,106 28,034 157,140 - 559,820 44,848 604,668 Gross profit (loss) - 123,866 1,325 125,191 - 475,895 3,670 479,565 Operating expense: Sales and Marketing 10,125 121,206 57,594 188,925 15,903 462,779 75,581 554,263 Research and development - 91,428 - 91,428 - 143,481 - 143,481 General and administrative 223,183 234,715 31,082 488,980 898,853 872,888 90,289 1,862,030 Total operating expenses 233,308 447,349 88,676 769,333 914,756 1,479,148 165,870 2,559,774 Operating loss $ (233,308 ) $ (323,483 ) $ (87,351 ) $ (644,142 ) $ (914,756 ) $ (1,003,253 ) $ (162,200 ) $ (2,080,209 ) Other income (expense): Interest expense (112,690 ) (284,168 ) Interest expense - related party (4,020 ) (156,170 ) Change in derivative liability 331,724 2,156,203 Gain on settlement - 625,461 Loss on debt modification (6,924 ) (26,905 ) Total other income, net 208,090 2,314,421 Income before provision for income taxes (436,052 ) 234,212 Provision for income taxes - 2,210 Net income $ (436,052 ) $ 232,002

Description of Business and S27

Description of Business and Summary of Significant Accounting Policies (Details Textual) - USD ($)	May. 01, 2015	Jul. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2013
Description of Business and Summary of Significant Accounting Policies (Textual)
Cash			$ 134,059	$ 72,860	$ 134,059	$ 72,860	$ 241,691	$ 48,370	$ 568
Working capital deficit					471,449
Loss from operations			$ (644,142)	$ (1,162,585)	$ (2,080,209)	$ (1,378,385)
Subsequent Event [Member]
Description of Business and Summary of Significant Accounting Policies (Textual)
Description of acquired entity	50/50 share (payable monthly based on actual net revenue collections.
Subsequent Event [Member] | Dr. Mark Scialdone [Member]
Description of Business and Summary of Significant Accounting Policies (Textual)
Common stock shares issued		150,000
Subsequent Event [Member] | BetterChem Consulting, Inc. [Member]
Description of Business and Summary of Significant Accounting Policies (Textual)
Acquired controlling interest percentage			80.00%		80.00%
Description of acquired entity		In consideration for the issuance of the shares to Dr. Scialdone, the Company acquired 80 shares of the common stock of BetterChem which represents 80% of the issued and outstanding shares of BetterChem. Dr. Scialdone retained a 20% interest in BetterChem.
Accounts payable		$ 8,500
Common stock shares issued		250,000
Common stock value		$ 67,500
Description of share exchange agreement		In the event of a change in control of BetterChem or a sale of all or substantially all of the assets of BetterChem during the two year period, the additional 150,000 shares shall automatically vest and be payable in full to Dr. Scialdone and any salary compensation due Dr. Scialdone under the 2 year term of his employment agreement with the Company dated May 1, 2015, or extensions of that Employment Agreement which the parties may thereafter execute, shall be accelerated and shall be due and payable in full within 30 days of the event of change in control of BetterChem.
Interest rate		80.00%
Subsequent Event [Member] | BetterChem Consulting, Inc. [Member] | One Year Anniversary [Member]
Description of Business and Summary of Significant Accounting Policies (Textual)
Description of share exchange agreement		On the one year anniversary of the closing, Dr. Scialdone shall be entitled to an additional 75,000 shares if BetterChem has generated at least $100,000 in gross revenues beginning on the date of closing and up to the one year anniversary of the closing. The additional stock issuance will be calculated on a pro rata basis (i.e. If BetterChem only generates $50,000 in gross revenues in the first year then Dr. Scialdone will be entitled to only 37,500 shares).
Subsequent Event [Member] | BetterChem Consulting, Inc. [Member] | Two Year Anniversary [Member]
Description of Business and Summary of Significant Accounting Policies (Textual)
Description of share exchange agreement		On the two year anniversary of the closing, Dr. Scialdone shall be entitled to an additional 75,000 shares if BetterChem has generated at least $100,000 in gross revenues beginning on the one year anniversary of the closing up to the two year anniversary of the closing. The additional stock issuance will be calculated on a pro rata basis (i.e. If BetterChem only generates $50,000 in gross revenues in the second year then Dr. Scialdone will be entitled to only 37,500 shares).
Subsequent Event [Member] | BetterChem Consulting, Inc. [Member] | Dr. Mark Scialdone [Member]
Description of Business and Summary of Significant Accounting Policies (Textual)
Acquired controlling interest percentage		80.00%
Restricted common stock issued		400,000

Accounting Policies and Basis28

Accounting Policies and Basis of Presentation (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Assets
Cash and cash equivalents	$ 134,059	$ 48,370
Total assets measured at fair value	134,059	48,370
Liabilities
Derivative instruments	308,029	2,464,232
Total liabilities measured at fair value	308,029	2,464,232
Level 1 [Member]
Assets
Cash and cash equivalents	134,059	48,370
Total assets measured at fair value	$ 134,059	$ 48,370
Liabilities
Derivative instruments
Total liabilities measured at fair value
Level 2 [Member]
Assets
Cash and cash equivalents
Total assets measured at fair value
Liabilities
Derivative instruments	$ 308,029	$ 2,464,232
Total liabilities measured at fair value	$ 308,029	$ 2,464,232
Level 3 [Member]
Assets
Cash and cash equivalents
Total assets measured at fair value
Liabilities
Derivative instruments
Total liabilities measured at fair value

Accounting Policies and Basis29

Accounting Policies and Basis of Presentation (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Accounting Policies and Basis of Presentation [Abstract]
Weighted average common shares outstanding used in calculating basic earnings per share			11,253,868
Effect of preferred stock			500,000
Effect of convertible notes payable			1,924,046
Effect of options and warrants			197,012
Weighted average common and common equivalent shares used in calculating diluted earnings per share	11,925,400	8,490,049	13,874,926	7,059,138
Net income as reported	$ (436,052)	$ (1,358,587)	$ 232,002	$ (31,163,951)
Add - Interest on convertible notes payable			427,240
Net income available to common stockholders			$ 659,242

Accounting Policies and Basis30

Accounting Policies and Basis of Presentation (Details 2) - shares	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Diluted shares outstanding	11,925,400	8,490,049	13,874,926	7,059,138
Convertible Notes [Member]
Diluted shares outstanding		901,228		901,228
Series A Preferred Stock [Member]
Diluted shares outstanding		5,000,000		5,000,000
Common Stock Options [Member]
Diluted shares outstanding		642,400		780,976
Common Stock Warrants [Member]
Diluted shares outstanding		30,701		18,804

Accounting Policies and Basis31

Accounting Policies and Basis of Presentation (Details 3) - $ / shares	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Weighted average variables used in the Black Scholes model
Stock Price at Grant Date	$ 0.73	$ 1.66
Dividend Yield
Exercise Price	$ 0.73	$ 1.66
Risk Free Interest Rate	2.20%	2.50%
Volatility	380.00%	400.00%
Average Life	10 years	10 years

Accounting Policies and Basis32

Accounting Policies and Basis of Presentation (Details Textual)	3 Months Ended		9 Months Ended
	Jun. 30, 2015USD ($)supplier	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)suppliershares	Jun. 30, 2014USD ($)shares
Business Combination, Separately Recognized Transactions [Line Items]
Number of suppliers | supplier	2		2
Credit risk rate	68.00%		70.00%
Purchase interest rate			50.00%
Estimated useful lives			3 years
Research and development expense	$ 91,428	$ 109,540	$ 143,481	$ 138,627
Number of options excluded from the compution of diluted shares outstanding | shares			110,000	125,000
Kyle Tracey [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Credit risk rate	36.00%		11.00%
Purchases of HIVE Glass	$ 60,000		$ 60,000

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Fixed Assets [Abstract]
Molds and Tooling	$ 157,655	$ 122,555
Leasehold improvements	29,795
Accumulated depreciation	(66,168)	$ (16,178)
Fixed assets, net	$ 121,282	$ 106,377

Fixed Assets (Details Textual)

Fixed Assets (Details Textual) - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Fixed Assets [Abstract]
Depreciation	$ 49,990

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Summary of Accrued Expenses:
Accrued interest	$ 24,747	$ 16,300
Accrued interest - related party	20,480	18,325
Accrued wages and taxes	48,561	108,374
Other	28,130	26,514
Accrued expenses	$ 121,918	$ 169,513

Third Party Debt (Details)

Third Party Debt (Details)	Jul. 04, 2015USD ($)$ / sharesshares	Jun. 04, 2015USD ($)shares	Mar. 12, 2015USD ($)$ / sharesshares	Feb. 10, 2015USD ($)$ / shares	Dec. 02, 2014USD ($)	Oct. 28, 2014USD ($)$ / sharesshares	Mar. 19, 2014USD ($)$ / shares	Feb. 11, 2014USD ($)investors$ / shares	Feb. 18, 2014USD ($)$ / sharesshares	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 03, 2014USD ($)$ / shares	Sep. 30, 2014USD ($)
Third Party Debt (Textual)
Principal amount														$ 500,000
Original issue discount										$ 400,000		$ 400,000
Interest Expense										112,690	$ 112,812	284,168	$ 164,471
Deferred financing costs										34,211		34,211
Deferred financing costs, long-term										5,105		$ 5,105
Net proceeds													328,463
Convertible notes payable, current										1,034,949		$ 1,034,949			$ 187,667
Convertible notes payable, long-term										46,667		46,667			178,200
Unamortized discount convertible notes payable, current										$ 261,717		$ 261,717			32,333
Unamortized discount convertible notes payable, non current															$ 19,800
Converted Amount			$ 20,000
Converted shares | shares			40,000
Subsequent Event [Member]
Third Party Debt (Textual)
Conversion price | $ / shares	$ 0.19
Convertible Notes payable	$ 46,667
Accrued interest	$ 4,295
Converted shares | shares	263,141
Securities Purchase Agreement [Member]
Third Party Debt (Textual)
Amortized discount to interest expense										$ 8,333		$ 19,444
Original issue discount														50,000
Transaction expenses					$ 10,000
Finder's fee														25,000
Deferred financing costs										45,940		45,940
Net proceeds					475,000
Amortization of interest expense										7,657		17,866
Unsecured convertible promissory note principal amount														$ 560,000
$2M Securities Purchase Agreement [Member]
Third Party Debt (Textual)
Principal amount										2,000,000		2,000,000
Interest rate				10.00%
Conversion price | $ / shares				$ 0.50
Amortized discount to interest expense										25,113		36,349
Discount related to beneficial conversion feature												108,641
Original issue discount				$ 182,000
Convertible Notes payable				1,808,000
Accrued interest										14,500		14,500
Interest Expense										10,111		14,500
Transaction expenses				$ 10,000
Value of note issued										400,000		800,000
Original issue discount of note										38,400		76,800
Net proceeds										361,600		723,200
Amortization of interest expense										17,600		22,400
Unamortized discount convertible notes payable, current										673,308		673,308
Total unamortized discounts										126,692		126,692
Percentage of premium amount				25.00%
Percentage of conversion price				70.00%
Unsecured convertible promissory note principal amount				$ 2,000,000
Minimum [Member] | $2M Securities Purchase Agreement [Member]
Third Party Debt (Textual)
Principal amount										$ 800,000		$ 800,000
6% Convertible Notes [Member]
Third Party Debt (Textual)
Principal amount								$ 230,000
Interest rate								6.00%		6.00%		6.00%
Amortized discount to interest expense										$ 0		$ 33,235
Discount related to beneficial conversion feature								$ 92,000
Convertible Notes payable			$ 17,200
Number of accredited investors | investors								10
Conversion description								The conversion price of these 6% Notes is the average of the fifteen (15) lowest daily VWAP's occurring during the twenty (20) consecutive trading days immediately preceding the date each Holder elects convert all of their 6% Note minus a discount of 40%.
Accrued interest										550		550
Interest Expense										3,607		2,705
Percentage of note outstanding			6.00%
Fair value of loss on debt			$ 23,443
Converted Amount			$ 80,000
Converted shares | shares			160,000
Converted shares outstanding			$ 30,000
Proceeds from initial investor												800,000
6% Convertible Notes [Member] | Securities Purchase Agreement [Member]
Third Party Debt (Textual)
Deferred financing costs										28,074		28,074
6% Convertible Notes [Member] | Minimum [Member]
Third Party Debt (Textual)
Maturity date								Feb. 28, 2015
Conversion price | $ / shares			$ 0.50					$ 1
6% Convertible Notes [Member] | Maximum [Member]
Third Party Debt (Textual)
Maturity date								Mar. 31, 2015
Conversion price | $ / shares			$ 1					$ 3
10% Convertible Notes [Member] | Securities Purchase Agreement [Member]
Third Party Debt (Textual)
Interest rate														10.00%
Conversion price | $ / shares														$ 0.50
Amortized discount to interest expense										28,000		65,333
Discount related to beneficial conversion feature					$ 168,000
Conversion description					The Note bears interest at the rate of 10% per annum and is convertible into common stock of the Company at a conversion price per share of 70% of the average of the three (3) lowest Closing Sale Prices in the ten (10) Trading Days immediately preceding the applicable Conversion (subject to adjustment in the event of stock splits, stock dividends, and similar transactions, and in the event of subsequent sales of common stock at a lower purchase price (subject to certain exceptions))(the "Conversion Price"). In no event will the Conversion Price be less than $0.50 per share.
Repayment of debt description					Repayment of principal on the Note, together with accrued interest thereon, is due in twelve monthly installments, commencing six months from issuance. The Company may make such payments in cash (in which event the Company will pay a 25% premium) or, subject to certain conditions, in shares of common stock valued at the lower of the Conversion Price or 70% of the average of the three (3) lowest Closing Sale Prices in the ten (10) Trading Days immediately preceding the applicable payment date.
8% Convertible Note [Member]
Third Party Debt (Textual)
Principal amount							$ 198,000		$ 20,000
Maturity date							Nov. 19, 2014		Feb. 18, 2016
Interest rate							8.00%		8.00%
Conversion price | $ / shares						$ 1			$ 0.498
Amortized discount to interest expense											$ 1,000		$ 1,667
Discount related to beneficial conversion feature							$ 158,400		$ 8,000
Original issue discount									5,333
Convertible Notes payable						$ 198,000	$ 198,000
Accrued and unpaid interest						9,764			$ 1,100
Conversion description							The conversion price for the Investor Note is eighty percent (80%) of the average of the three (3) lowest daily closing bid prices (the 3 lowest prices will be calculated on a VWAP basis) occurring during the ten (10) consecutive Trading Days immediately preceding the applicable conversion date on which the holder elects to convert.		The conversion price for the notes was the lowest market closing price per share within the previous twenty (20) market days of the date of conversion minus a discount of forty percent (40%).
Unamortized discount convertible notes payable, non current						$ 19,800
Converted shares | shares						207,764			42,370
8% Convertible Note [Member] | Minimum [Member]
Third Party Debt (Textual)
Conversion price | $ / shares							$ 1
8% Convertible Note [Member] | Maximum [Member]
Third Party Debt (Textual)
Conversion price | $ / shares							$ 3
Convertible Note [Member]
Third Party Debt (Textual)
Principal amount		$ 46,667
Accrued interest		28,871								3,640		3,640
Interest Expense										14,156		32,511
Interest expense in excess of fair market value of the stock issued		$ 14,435
Convertible notes payable, current										333,444		333,444
Convertible notes payable, long-term										46,667		46,667
Unamortized discount convertible notes payable, current										226,556		226,556
Unamortized discount convertible notes payable, non current										$ 0		$ 0
Converted shares | shares		220,949

Related Party Debt (Details)

Related Party Debt (Details) - USD ($)

Jul. 04, 2015

Mar. 12, 2015

Jan. 22, 2015

Dec. 04, 2014

Oct. 28, 2014

Aug. 11, 2014

May. 12, 2014

Mar. 19, 2014

Mar. 17, 2014

Feb. 28, 2014

Dec. 07, 2013

Feb. 18, 2014

Jun. 30, 2015

Mar. 31, 2015

Jun. 30, 2014

Mar. 31, 2015

Jun. 30, 2015

Jun. 30, 2014

Sep. 30, 2014

Dec. 03, 2014

Sep. 30, 2013

Related Party Debt (Textual)

Transaction expenses

$ 20,000

Unamortized discount convertible notes payable, non current

$ 19,800

Notes payable, related parties

$ 265,000

$ 265,000

341,290

Accrued interest

24,747

24,747

16,300

Interest Expense

112,690

$ 112,812

284,168

$ 164,471

Principal amount

$ 500,000

Unamortized discount

400,000

400,000

Common stock issued on conversion

40,000

Gain on extinguishment of debt

625,461

Hive Asset Acquisition [Member]

Related Party Debt (Textual)

Interest rate

6.00%

Accrued interest

19,062

19,062

Maturity date

Feb. 27, 2016

Interest expense related to notes payable

3,792

11,377

Principal amount

$ 250,000

8% Convertible Note [Member]

Related Party Debt (Textual)

Interest rate

8.00%

8.00%

Unamortized discount convertible notes payable, non current

$ 19,800

Accounts payable, related parties

$ 20,000

Maturity date

Nov. 19, 2014

Feb. 18, 2016

Principal amount

$ 198,000

$ 20,000

Conversion price

$ 1

$ 0.498

Unamortized discount

$ 5,333

Common stock issued on conversion

207,764

42,370

Discount related to beneficial conversion feature

$ 158,400

$ 8,000

Amortized discount to interest expense

$ 1,000

$ 1,667

Conversion description

The conversion price for the Investor Note is eighty percent (80%) of the average of the three (3) lowest daily closing bid prices (the 3 lowest prices will be calculated on a VWAP basis) occurring during the ten (10) consecutive Trading Days immediately preceding the applicable conversion date on which the holder elects to convert.

The conversion price for the notes was the lowest market closing price per share within the previous twenty (20) market days of the date of conversion minus a discount of forty percent (40%).

Accrued and unpaid interest

$ 9,764

$ 1,100

Subsequent Event [Member]

Related Party Debt (Textual)

Conversion price

$ 0.19

Common stock issued on conversion

263,141

Minimum [Member] | 8% Convertible Note [Member]

Related Party Debt (Textual)

Conversion price

$ 1

Maximum [Member] | 8% Convertible Note [Member]

Related Party Debt (Textual)

Conversion price

$ 3

Related Party [Member]

Related Party Debt (Textual)

Accounts payable, related parties

$ 40,000

Maturity date

May 1, 2016

Joseph Andreae [Member]

Related Party Debt (Textual)

Accounts payable outstanding

$ 12,828

Interest rate

6.00%

6.00%

Notes payable, related parties

$ 12,828

$ 40,000

Accrued interest

$ 1,348

Maturity date

Nov. 30, 2014

May 1, 2016

Repayament of principal balance

40,000

Joseph Andreae [Member] | Andreae Note II [Member]

Related Party Debt (Textual)

Accrued interest

240

Repayament of principal balance

$ 12,828

Jerome Kaiser [Member] | 8% Convertible Note [Member]

Related Party Debt (Textual)

Interest rate

8.00%

Accrued interest

$ 4,000

$ 4,000

Maturity date

Mar. 17, 2015

Future principal payments of related party notes payable

$ 50,000

Notes payable

50,000

Principal amount

50,000

50,000

Discount related to beneficial conversion feature

$ 10,000

Amortized discount to interest expense

$ 1,667

$ 4,167

Conversion description

The conversion price for the Kaiser Note is the market closing price of the market day immediately preceding the date of conversion minus twenty percent (20%).

Kyle [Member] | 6% Note [Member]

Related Party Debt (Textual)

Interest rate

6.00%

Notes payable, related parties

40,000

$ 40,000

Interest expense related to notes payable

$ 1,098

Conversion price

$ 1

Unamortized discount

13,333

Common stock issued on conversion

41,098

Discount related to beneficial conversion feature

$ 16,000

Amortized discount to interest expense

6,667

Kyle Tracey [Member] | 8% Convertible Note [Member]

Related Party Debt (Textual)

Interest rate

8.00%

Accounts payable, related parties

$ 10,612

Maturity date

Feb. 18, 2016

Interest expense related to notes payable

$ 584

Principal amount

$ 10,612

Conversion price

$ 0.498

Unamortized discount

2,830

Common stock issued on conversion

22,481

Discount related to beneficial conversion feature

$ 4,245

Amortized discount to interest expense

1,415

Conversion description

The conversion price for the Tracey Note was the lowest market closing price per share within the previous twenty (20) market days of the date of conversion minus a discount of forty percent (40%).

Kyle Tracey Two [Member] | 8% Convertible Note [Member]

Related Party Debt (Textual)

Interest rate

8.00%

Accounts payable, related parties

$ 11,042

Maturity date

May 12, 2016

Interest expense related to notes payable

$ 407

Principal amount

$ 11,042

Conversion price

$ 0.498

Unamortized discount

3,497

Common stock issued on conversion

22,989

Discount related to beneficial conversion feature

$ 4,417

Amortized discount to interest expense

920

Conversion description

The conversion price for the Tracey Note II was the lowest market closing price per share within the previous twenty (20) market days of the date of conversion minus a discount of forty percent (40%).

Michael Cook [Member] | 8% Convertible Note [Member]

Related Party Debt (Textual)

Interest rate

8.00%

Accounts payable, related parties

$ 11,825

Maturity date

May 12, 2016

Interest expense related to notes payable

$ 435

Principal amount

$ 11,825

Conversion price

$ 0.498

Unamortized discount

3,745

Common stock issued on conversion

24,619

Discount related to beneficial conversion feature

$ 4,730

Amortized discount to interest expense

$ 985

Conversion description

The conversion price for the Cook Note was the lowest market closing price per share within the previous twenty (20) market days of the date of conversion minus a discount of forty percent (40%).

Mr. Cook [Member] | 8% Convertible Note [Member]

Related Party Debt (Textual)

Interest rate

8.00%

Accounts payable, related parties

$ 15,115

Maturity date

Aug. 11, 2016

Interest expense related to notes payable

$ 255

Principal amount

$ 15,115

$ 15,115

Conversion price

$ 0.498

Unamortized discount

5,542

Common stock issued on conversion

30,864

Discount related to beneficial conversion feature

$ 6,046

Conversion description

The conversion price for the Cook Note II was the lowest market closing price per share within the previous twenty (20) market days of the date of conversion minus a discount of forty percent (40%).

Mr. Tracey [Member] | 8% Convertible Note [Member]

Related Party Debt (Textual)

Interest rate

8.00%

Accounts payable, related parties

$ 216,001

Maturity date

Aug. 11, 2016

Interest expense related to notes payable

$ 3,645

Principal amount

$ 216,001

$ 216,001

Conversion price

$ 0.498

Unamortized discount

79,200

Common stock issued on conversion

441,057

Discount related to beneficial conversion feature

$ 86,401

Conversion description

The conversion price for the Tracey Note III was the lowest market closing price per share within the previous twenty (20) market days of the date of conversion minus a discount of forty percent (40%).

Shareholder [Member]

Related Party Debt (Textual)

Interest rate

6.00%

Notes payable, related parties

$ 23,462

Accounts payable, related parties

$ 15,000

Accrued interest

$ 1,504

1,417

1,417

Maturity date

Dec. 1, 2016

Interest expense related to notes payable

$ 228

$ 685

Notes payable

20,000

Gain on extinguishment of debt

$ 3,462

Commitments and Contingencies38

Commitments and Contingencies (Details)	9 Months Ended
	Jun. 30, 2015
Year 1 [Member] | Up to $200,000 gross revenue [Member]
Bonus compensation rate	25.00%
Year 1 [Member] | From $200,000 - $400,000 gross revenue [Member]
Bonus compensation rate	5.00%
Year 1 [Member] | From $400,000 - $600,000 gross revenue [Member]
Bonus compensation rate	7.50%
Year 1 [Member] | Above $600,000 gross revenue [Member]
Bonus compensation rate	10.00%
Year 2 [Member] | Up to $200,000 gross revenue [Member]
Bonus compensation rate	2.50%
Year 2 [Member] | From $200,000 - $400,000 gross revenue [Member]
Bonus compensation rate	5.00%
Year 2 [Member] | From $400,000 - $600,000 gross revenue [Member]
Bonus compensation rate	7.50%
Year 2 [Member] | Above $600,000 gross revenue [Member]
Bonus compensation rate	10.00%

Commitments and Contingencies39

Commitments and Contingencies (Details Textual) - USD ($)	Dec. 15, 2015	May. 11, 2015	May. 01, 2015	Jan. 31, 2015	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2014	Mar. 31, 2014
Other Commitments [Line Items]
Change in warrant liability					$ (331,724)			$ (2,156,203)	$ 29,528,844
Warrant liability					308,029			308,029		$ 2,464,232
Net proceeds from settlement						$ 62,930		62,930
Vendor credits					325,000	$ 200,000		325,000
Treasury stock, value					$ 367,531			$ 367,531
Treasury stock, shares					440,625			440,625
Gain on settlement								$ 625,461
Loss on settlement of stock	$ 257,930
Chief Science Officer [Member]
Other Commitments [Line Items]
Term of executive employment agreement			P2Y
Annual salary			$ 102,000
Bonus compensation description								50/50 share (payable monthly based on actual net revenue collections.
Percentage of net royalties received by company								15.00%
Percentage of net profit received by company								5.00%
Director [Member]
Other Commitments [Line Items]
Restricted common stock issued		100,000
Restricted common stock vest quarterly		25,000
Subsequent Event [Member]
Other Commitments [Line Items]
Common stock for compensation				440,625
Warrant [Member] | Maximum [Member]
Other Commitments [Line Items]
Shares issued, price per share											$ 7.25
Warrant [Member]
Other Commitments [Line Items]
Shares issued, price per share											$ 7.25
Long term warrant liability											$ 29,430,022
Closing stock shares											4,407,200
Change in derivative liability								$ 2,156,203
Fair value of warrant liability					$ 1,184,727			1,184,727
Warrant liability					$ 308,029			$ 308,029
Warrant [Member] | Minimum [Member]
Other Commitments [Line Items]
Shares issued, price per share											$ 4.72

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - Jun. 30, 2015 - USD ($)	Total
Warrant [Member]
STOCK OPTIONS/WARRANTS:
Options/ Warrants outstanding, Shares, Beginning balance	1,184,726
Options/ Warrants issued/granted
Option/ Warrants exercised
Option/ Warrants Cancelled/forfeited/expired
Options/ Warrants Outstanding, Shares, Ending Balance	1,184,726
Option/ Warrents Weighted Average Exercise Price, Beginning balance	$ 0.114
Option/ Warrents issued/granted, Weighted Average Exercise Price
Option/ Warrents exercised, Weighted Average Exercise Price
Option/ Warrents Cancelled/forfeited/expired, Weighted Average Exercise Price
Option/ Warrents Weighted Average Exercise Price, Ending Balance	$ 0.114
Options/ Warrants outstanding, Weighted Average Remaining Contractual Term, Beginning	1 year 7 months 6 days
Options/ Warrants outstanding, Weighted Average Remaining Contractual Term, Ending	10 months 24 days
Option/ Warrents Outstanding, Aggregate Intrinsic Value, Beginning balance	$ 7,217,234
Option/ Warrents Outstanding, Aggregate Intrinsic value, Balance	$ 739,812
Stock Options [Member]
STOCK OPTIONS/WARRANTS:
Options/ Warrants outstanding, Shares, Beginning balance	1,150,000
Options/ Warrants issued/granted	995,000
Option/ Warrants exercised
Option/ Warrants Cancelled/forfeited/expired	(1,150,000)
Options/ Warrants Outstanding, Shares, Ending Balance	995,000
Options/ Warrants exercisable, Shares	497,500
Option/ Warrents Weighted Average Exercise Price, Beginning balance	$ 2.92
Option/ Warrents issued/granted, Weighted Average Exercise Price	$ 0.73
Option/ Warrents exercised, Weighted Average Exercise Price
Option/ Warrents Cancelled/forfeited/expired, Weighted Average Exercise Price	$ 2.92
Option/ Warrents Weighted Average Exercise Price, Ending Balance	0.73
Options/ Warrants exercisable, Weighted Average Exercise Price	$ 0.73
Options/ Warrants outstanding, Weighted Average Remaining Contractual Term, Beginning	8 years 8 months 12 days
Options/ Warrants granted, Weighted Average Remaining Contractual Term	10 years
Options/ Warrants cancelled/forfeited/expired, Weighted Average Remaining Contractual Term	9 years 2 months 12 days
Options/ Warrants outstanding, Weighted Average Remaining Contractual Term, Ending	9 years 4 months 24 days
Options/ Warrants exercisable, Weighted Average Remaining Contractual Term	9 years 4 months 24 days
Option/ Warrents Outstanding, Aggregate Intrinsic Value, Beginning balance	$ 4,648,294
Option/ Warrents Outstanding, Aggregate Intrinsic value, Balance	29,805
Options/ Warrants exercisable, Aggregate Intrinsic value	$ 14,902

Stockholders' Deficit (Details

Stockholders' Deficit (Details Textual) - Related Party [Domain]

Jul. 04, 2015shares

Jun. 01, 2015USD ($)$ / sharesshares

May. 11, 2015shares

Mar. 12, 2015USD ($)Employeeshares

Oct. 20, 2014USD ($)$ / sharesshares

Feb. 11, 2014

Dec. 22, 2014USD ($)$ / sharesshares

Jun. 27, 2014USD ($)$ / sharesshares

Jun. 19, 2014shares

Mar. 31, 2015USD ($)

Dec. 31, 2013USD ($)

Mar. 31, 2015USD ($)

Jun. 30, 2015USD ($)$ / sharesshares

Jun. 30, 2014USD ($)

Sep. 30, 2014USD ($)shares

Dec. 03, 2014USD ($)

Aug. 11, 2014USD ($)

Jan. 31, 2014USD ($)

Stockholders' Deficit (Textual)

Common stock, shares authorized

1,000,000,000

1,000,000,000

Preferred stock, shares authorized

100,000,000

100,000,000

Convertible price, description

The conversion price of these 6% Notes is the average of the fifteen (15) lowest daily VWAPs occurring during the twenty (20) consecutive trading days immediately preceding the date each Holder elects convert all of their 6% Note minus a discount of 40%.

Shares authorized

2,000,000

Principal amount | $

$ 500,000

Common stock issued on conversion

40,000

Common stock issued for services | $

$ 36,769

Conversion of unpaid wages | $

96,487

Issuance of common stock | $

$ 36,769

$ 122,800

Issuance of fair market value | $

328,463

Cost of Revenue [Member]

Stockholders' Deficit (Textual)

Fair value of the stock vested issuance | $

$ 9,150

$ 9,150

Selling and Marketing Expense [Member]

Stockholders' Deficit (Textual)

Fair value of the stock vested issuance | $

9,150

9,150

General and Administrative Expense [Member]

Stockholders' Deficit (Textual)

Fair value of the stock vested issuance | $

$ 195,200

$ 195,200

$ 195,200

Under 2014 Stock Option Plan [Member]

Stockholders' Deficit (Textual)

Vesting rights, Description

The options vest 25% at grant and 25% each subsequent six (6) months from the date of grant.

The options vest 25% at grant and 25% each subsequent six (6) months from the date of grant.

Options/ Warrants issued/granted

20,000

775,000

Stock option cancelled

20,000

225,000

Option/ Warrents Granted, Weighted Average Exercise Price | $ / shares

$ 0.83

$ 0.70

Stock option granted value | $

$ 16,600

$ 542,500

Share-based compensation expense | $

$ 4,150

$ 135,625

Number of options vested

5,000

193,750

Stock Options [Member]

Stockholders' Deficit (Textual)

Options/ Warrants issued/granted

995,000

Stock option cancelled

(1,150,000)

Option/ Warrents Granted, Weighted Average Exercise Price | $ / shares

$ 0.73

Share-based compensation expense | $

$ 0

$ 681,375

437,312

Options available for issuance under the plan

1,005,000

Non Employeeb Stock Option [Member]

Stockholders' Deficit (Textual)

Share-based compensation expense | $

$ 71,262

$ 0

September 30, 2015 [Member] | Stock Options [Member]

Stockholders' Deficit (Textual)

Share-based compensation expense | $

681,375

September 30, 2016 [Member] | Stock Options [Member]

Stockholders' Deficit (Textual)

Share-based compensation expense | $

283,300

Consulting Agreements [Member]

Stockholders' Deficit (Textual)

Vesting rights, Description

The options vest 25% at grant and 25% each subsequent six (6) months from the date of grant.

Options/ Warrants issued/granted

200,000

Option/ Warrents Granted, Weighted Average Exercise Price | $ / shares

$ 0.83

Stock option granted value | $

$ 166,000

Options to purchase shares

100,000

Share-based compensation expense | $

$ 41,500

Additional expenses | $

$ 3,000

Non employee options

200,000

Number of options vested

50,000

Subsequent Event [Member]

Stockholders' Deficit (Textual)

Vesting rights, Description

The options vest 25% at grant and 25% each subsequent six (6) months from the date of grant.

Option/ Warrents Granted, Weighted Average Exercise Price | $ / shares

$ 0.70

Options to purchase shares

175,000

Common stock issued on conversion

263,141

Stock option forfeitured

217,500

10% Convertible Note [Member]

Stockholders' Deficit (Textual)

Principal amount | $

$ 100,000

Series A Preferred Stock

Stockholders' Deficit (Textual)

Shares issued during period

500,000

Preferred stock, shares authorized

500,000

Common stock issued for bonuses, Shares

Common Stock [Member]

Stockholders' Deficit (Textual)

Common stock issued for services, Shares

60,277

Common stock issued for services | $

$ 1

Conversion of unpaid wages, Shares

158,175

Conversion of unpaid wages | $

$ 2

Common stock issued for bonuses, Shares

440,000

Preferred Stock [Member]

Stockholders' Deficit (Textual)

Shares issued during period

500,000

Preferred stock, shares authorized

100,000,000

Description of asset purchase agreement

Series A Shares are entitled to vote at a 15-1 ratio to Common Stock

Kyle Tracey [Member]

Stockholders' Deficit (Textual)

Options to purchase shares

175,000

100,000

Conversion of unpaid wages, Shares

97,898

Conversion of unpaid wages | $

$ 59,718

Kyle Tracey [Member] | Subsequent Event [Member]

Stockholders' Deficit (Textual)

Options/ Warrants issued/granted

30,000

25,000

Principal amount | $

$ 216,001

Board Of Directors And Shareholders [Member]

Stockholders' Deficit (Textual)

Vesting rights, Description

The options vest 25% at grant and 25% each subsequent six (6) months from the date of grant.

Options/ Warrants issued/granted

775,000

1,000,000

Option/ Warrents Granted, Weighted Average Exercise Price | $ / shares

$ 1.66

Stock option granted value | $

$ 1,000,000

Options to purchase shares

225,000

520,000

Share-based compensation expense | $

$ 1,660,000

Compensation cost upon grant date | $

$ 415,000

Additional expenses | $

$ 22,312

Non employee options

212,500

Number of options vested

250,000

Consultant [Member]

Stockholders' Deficit (Textual)

Convertible price, description

A one-time pro rata adjustment of up to ten-for-one (10-1) based upon the Company generating aggregate gross revenues over the two years of at least $8,000,000 (e.g. If the Company generates only $4,000,000 in aggregate gross revenues over the two year period then the convertible ratio will adjust to 5-1). In no event will the issuance convert into more than 5,000,000 shares of common stock of the Company.

Stock option forfeitured

237,500

Stock option forfeitured exercise price | $ / shares

$ 1.66

Joseph Andreae [Member]

Stockholders' Deficit (Textual)

Options to purchase shares

175,000

190,000

Joseph Andreae [Member] | Subsequent Event [Member]

Stockholders' Deficit (Textual)

Options/ Warrants issued/granted

30,000

Principal amount | $

12,828

Chief Financial Officer [Member]

Stockholders' Deficit (Textual)

Options to purchase shares

175,000

Michael Cook [Member]

Stockholders' Deficit (Textual)

Options to purchase shares

25,000

Conversion of unpaid wages, Shares

60,277

Conversion of unpaid wages | $

$ 36,769

Restricted common stock issued

100,000

Michael Cook [Member] | Subsequent Event [Member]

Stockholders' Deficit (Textual)

Principal amount | $

$ 15,115

Board of Directors [Member]

Stockholders' Deficit (Textual)

Options/ Warrants issued/granted

60,000

Common stock issued for bonuses, Shares

30,000

Additional shares of restricted common stock, Granted

100,000

Number of employee | Employee

3

Restricted common stock issued

100,000

Shares issued, price per share | $ / shares

$ 1

Accrued legal services | $

$ 82,648

Prepaid legal expense | $

$ 17,352

Issuance of common stock | $

100,000

Issuance of fair market value | $

50,000

Additional consideration amount | $

$ 50,000

Officers, Employees And Consultants [Member]

Stockholders' Deficit (Textual)

Surrender of stock options

1,125,000

Officers, Employees And Consultants [Member] | Subsequent Event [Member]

Stockholders' Deficit (Textual)

Options/ Warrants issued/granted

1,005,000

Former Business Development Officer [Member]

Stockholders' Deficit (Textual)

Stock option forfeitured

100,000

Stock option forfeitured exercise price | $ / shares

$ 1.66

Former Business Development Officer [Member] | Subsequent Event [Member]

Stockholders' Deficit (Textual)

Stock option forfeitured

100,000

Employees [Member]

Stockholders' Deficit (Textual)

Stock option forfeitured

117,500

Stock option forfeitured exercise price | $ / shares

$ 1.66

Employees [Member] | Subsequent Event [Member]

Stockholders' Deficit (Textual)

Stock option forfeitured

117,500

Chief Executive Officer, President and Chief Operating Officer [Member]

Stockholders' Deficit (Textual)

Stock option forfeitured

190,000

Stock option forfeitured exercise price | $ / shares

$ 1.66

Chief Executive Officer, President and Chief Operating Officer [Member] | Subsequent Event [Member]

Stockholders' Deficit (Textual)

Stock option forfeitured

190,000

Intellectual Property (Details)

Intellectual Property (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Intellectual Property (Textual)
Trademarks	$ 123,150	$ 119,575
Pending patents	20,420	$ 14,890
Patents [Member]
Intellectual Property (Textual)
Pending patents	20,420
Trademarks [Member]
Intellectual Property (Textual)
Trademarks	$ 123,150

Segment Information (Details)

Segment Information (Details) - USD ($)		3 Months Ended		9 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue
Ceramics		$ 175,590		$ 958,333
Supply		10,382		10,382
Glass		67,000		67,000
Merchandise		26,859		46,018
Services		2,500		2,500
Total revenue		282,331		1,084,233
Cost of revenue
Ceramics		58,736		489,450
Supply		10,370		10,370
Glass		60,000		60,000
Merchandise		$ 28,035		$ 44,848
Services
Total cost of revenue	[1]	$ 157,140	$ 356,166	$ 604,668	$ 365,787
Gross profit (loss)		125,191	$ 5,615	479,565	$ 26,753
Operating expense:
Sales and Marketing	[2]	188,925		554,263
Research and development		91,428	$ 109,540	143,481	$ 138,627
General and administrative	[3]	488,980	1,058,660	1,862,030	1,266,511
Total operating expenses		769,333	1,168,200	2,559,774	1,405,138
Operating loss		(644,142)	(1,162,585)	(2,080,209)	(1,378,385)
Other income (expense):
Interest Expense		112,690	112,812	284,168	164,471
Interest expense - related party		4,020	$ 82,390	156,170	91,451
Change in warrant liability		$ (331,724)		(2,156,203)	$ 29,528,844
Gain on settlement				625,461
Loss on debt modification		$ 6,924		26,905
Total other income, net		208,090	$ (195,202)	2,314,421	$ (29,784,766)
Income before provision for income taxes		$ (436,052)	(1,357,787)	234,212	(31,163,151)
Provision for income taxes			800	2,210	800
Net income		$ (436,052)	$ (1,358,587)	$ 232,002	$ (31,163,951)
VAPE [Member]
Revenue
Ceramics
Supply
Glass
Merchandise
Services
Total revenue
Cost of revenue
Ceramics
Supply
Glass
Merchandise
Services
Total cost of revenue
Gross profit (loss)
Operating expense:
Sales and Marketing		$ 10,125		$ 15,903
Research and development
General and administrative		$ 223,183		$ 898,853
Total operating expenses		233,308		914,756
Operating loss		(233,308)		(914,756)
HIVE [Member]
Revenue
Ceramics		175,590		958,333
Supply		10,382		10,382
Glass		$ 67,000		$ 67,000
Merchandise
Services
Total revenue		$ 252,972		$ 1,035,715
Cost of revenue
Ceramics		58,736		489,450
Supply		10,370		10,370
Glass		$ 60,000		$ 60,000
Merchandise
Services
Total cost of revenue		$ 129,106		$ 559,820
Gross profit (loss)		123,866		475,895
Operating expense:
Sales and Marketing		121,206		462,779
Research and development		91,428		143,481
General and administrative		234,715		872,888
Total operating expenses		447,349		1,479,148
Operating loss		$ (323,483)		$ (1,003,253)
MARKETING [Member]
Revenue
Ceramics
Supply
Glass
Merchandise		$ 26,857		$ 46,018
Services		2,500		2,500
Total revenue		$ 29,359		$ 48,518
Cost of revenue
Ceramics
Supply
Glass
Merchandise		$ 28,034		$ 44,848
Services
Total cost of revenue		$ 28,034		$ 44,848
Gross profit (loss)		1,325		3,670
Operating expense:
Sales and Marketing		$ 57,594		$ 75,581
Research and development
General and administrative		$ 31,082		$ 90,289
Total operating expenses		88,676		165,870
Operating loss		$ (87,351)		$ (162,200)
[1]	Stock-based compensation was $2,075 and $0, and $41,408 and $0 for the three and nine months ended June 30, 2015 and 2014, respectively.
[2]	Stock-based compensation was $15,200 and $0, and $110,167 and $0 for the three and nine months ended June 30, 2015 and 2014, respectively.
[3]	Stock-based compensation was $126,250 and $437,312, and $529,799 and $437,312 for the three and nine months ended June 30, 2015 and 2014, respectively.

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Aug. 12, 2015	Aug. 05, 2015	Jun. 30, 2015	Dec. 03, 2014
Subsequent Event [Line Items]
Principal amount				$ 500,000
$2M Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Principal amount			$ 2,000,000
$2M Securities Purchase Agreement [Member] | Minimum [Member]
Subsequent Event [Line Items]
Principal amount			$ 800,000
Subsequent Event [Member] | Convertible Note Financing [Member]
Subsequent Event [Line Items]
Interest rate	8.00%
Maturity date	Jun. 12, 2016
Conversion description	The convertible note bears interest at the rate of 8% per annum and is convertible into common stock of the Company at any time after 180 days from issuance of the note at a conversion price per share equal to 58% of the average of the lowest trading price of the common stock in the thirteen (13) trading days immediately preceding the applicable conversion date. The Company has the option to prepay the convertible note in the first 180 days from closing subject to a prepayment penalty of 150% of principal plus interest.
Convertible note financing	$ 105,000	$ 517,000
Subsequent Event [Member] | BetterChem Consulting, Inc. [Member]
Subsequent Event [Line Items]
Acquired controlling interest percentage			80.00%